



Clinical trial results:

A Phase I/IIa, Open-label, Randomised, Controlled, Multi-country, Dose-escalation Study to Assess the Safety and Immunogenicity of AS37 in Combination with the Hepatitis B surface antigen (HBsAg), According to a 0-1 Schedule, in Healthy, HBs naïve, Adults aged 18-45 years

Summary

EudraCT number	2021-005629-25
Trial protocol	DE BE
Global end of trial date	29 November 2024

Results information

Result version number	v1 (current)
This version publication date	10 December 2025
First version publication date	10 December 2025

Trial information

Trial identification

Sponsor protocol code	215301
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline
Sponsor organisation address	Rue de l'Institut 89, Rixensart, Belgium, B-1330
Public contact	GSK Response Center, GlaxoSmithKline, 44 8664357343, GSKClinicalSupportHD@gsk.com
Scientific contact	GSK Response Center, GlaxoSmithKline, 44 8664357343, GSKClinicalSupportHD@gsk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	17 February 2025
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	29 November 2024
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the reactogenicity and safety in all study groups.

Protection of trial subjects:

Study participants were observed closely for at least 60 minutes after the administration of the study interventions. Appropriate medical treatment was readily available during the observation period in case of anaphylaxis or syncope.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	04 October 2022
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 22
Country: Number of subjects enrolled	Germany: 65
Country: Number of subjects enrolled	United Kingdom: 35
Worldwide total number of subjects	122
EEA total number of subjects	87

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	122
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

All enrolled participants received study intervention and were included in the Exposed set.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Blinding implementation details:

This is an open-label study.

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	HBs-alum Group
------------------	----------------

Arm description:

Participants received 3 doses of GSK's Hepatitis B (HBs) vaccine adjuvanted with aluminum hydroxide, at Day 1, Day 31 and Day 181.

Arm type	Experimental
Investigational medicinal product name	GSK's HB vaccine adjuvanted with aluminum hydroxide
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Intramuscular use

Dosage and administration details:

3 doses administered at Days 1, 31 and 181 in the non-dominant arm.

Arm title	HBs-AS03 Group
------------------	----------------

Arm description:

Participants received 2 doses of GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03, adjuvant system, at Day 1 and Day 31.

Arm type	Experimental
Investigational medicinal product name	GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant system
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder and solution for solution for injection
Routes of administration	Intramuscular use

Dosage and administration details:

2 doses administered at Days 1 and 31 in the non-dominant arm.

Arm title	HBs-AS04 Group
------------------	----------------

Arm description:

Participants received 2 doses of GSK's Hepatitis B vaccine adjuvanted with GSK's AS04, adjuvant system, at Day 1 and Day 31.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant system
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Intramuscular use
Dosage and administration details: 2 doses administered at Days 1 and 31 in the non-dominant arm.	
Arm title	HBs-AS37_formulation 1 (Low dose) Group
Arm description: Participants received 2 doses of GSK's HBsAg candidate vaccine adjuvanted with GSK's AS37 adjuvant system formulation 1 (Low dose), at Day 1 and Day 31.	
Arm type	Experimental
Investigational medicinal product name	GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for suspension for injection, Suspension for injection, Solution for injection
Routes of administration	Intramuscular use
Dosage and administration details: 2 doses administered at Days 1 and 31 in the non-dominant arm.	
Arm title	HBs-AS37_formulation 2 (High dose) Group
Arm description: Participants received 2 doses of GSK's HBsAg candidate vaccine adjuvanted with GSK's AS37 adjuvant system formulation 2 (High dose), at Day 1 and Day 31.	
Arm type	Experimental
Investigational medicinal product name	GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for suspension for injection, Suspension for injection, Solution for injection
Routes of administration	Intramuscular use
Dosage and administration details: 2 doses administered at Days 1 and 31 in the non-dominant arm.	

Number of subjects in period 1	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group
Started	25	25	24
Completed	24	23	23
Not completed	1	2	1
Not specified	1	-	1
Lost to follow-up	-	1	-
Consent withdrawal, not due to (S) AE	-	1	-

Number of subjects in period 1	HBs-AS37_formulation 1 (Low dose) Group	HBs-AS37_formulation 2 (High dose) Group
Started	25	23

Completed	24	23
Not completed	1	0
Not specified	-	-
Lost to follow-up	1	-
Consent withdrawal, not due to (S) AE	-	-

Baseline characteristics

Reporting groups

Reporting group title	HBs-alum Group
Reporting group description: Participants received 3 doses of GSK's Hepatitis B (HBs) vaccine adjuvanted with aluminum hydroxide, at Day 1, Day 31 and Day 181.	
Reporting group title	HBs-AS03 Group
Reporting group description: Participants received 2 doses of GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03, adjuvant system, at Day 1 and Day 31.	
Reporting group title	HBs-AS04 Group
Reporting group description: Participants received 2 doses of GSK's Hepatitis B vaccine adjuvanted with GSK's AS04, adjuvant system, at Day 1 and Day 31.	
Reporting group title	HBs-AS37_formulation 1 (Low dose) Group
Reporting group description: Participants received 2 doses of GSK's HBsAg candidate vaccine adjuvanted with GSK's AS37 adjuvant system formulation 1 (Low dose), at Day 1 and Day 31.	
Reporting group title	HBs-AS37_formulation 2 (High dose) Group
Reporting group description: Participants received 2 doses of GSK's HBsAg candidate vaccine adjuvanted with GSK's AS37 adjuvant system formulation 2 (High dose), at Day 1 and Day 31.	

Reporting group values	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group
Number of subjects	25	25	24
Age categorical Units: Subjects			
Adults (18-64 years)	25	25	24
Age continuous Units: years			
arithmetic mean	35.9	37.5	34.5
standard deviation	± 5.8	± 6.4	± 7.9
Sex: Female, Male Units: Participants			
MALE	14	15	14
FEMALE	11	10	10
Race/Ethnicity, Customized			
Asian and Black or African American are considered minority races in this study and are presented together under the category "Other Races".			
Units: Subjects			
Other Races	2	0	2
White	23	25	22

Reporting group values	HBs-AS37_formulation 1 (Low dose) Group	HBs-AS37_formulation 2 (High dose) Group	Total
Number of subjects	25	23	122
Age categorical Units: Subjects			
Adults (18-64 years)	25	23	122

Age continuous Units: years arithmetic mean standard deviation	38.6 ± 6.0	37.3 ± 7.7	-
Sex: Female, Male Units: Participants			
MALE	15	13	71
FEMALE	10	10	51
Race/Ethnicity, Customized			
Asian and Black or African American are considered minority races in this study and are presented together under the category "Other Races".			
Units: Subjects			
Other Races	2	1	7
White	23	22	115

End points

End points reporting groups

Reporting group title	HBs-alum Group
Reporting group description: Participants received 3 doses of GSK's Hepatitis B (HBs) vaccine adjuvanted with aluminum hydroxide, at Day 1, Day 31 and Day 181.	
Reporting group title	HBs-AS03 Group
Reporting group description: Participants received 2 doses of GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03, adjuvant system, at Day 1 and Day 31.	
Reporting group title	HBs-AS04 Group
Reporting group description: Participants received 2 doses of GSK's Hepatitis B vaccine adjuvanted with GSK's AS04, adjuvant system, at Day 1 and Day 31.	
Reporting group title	HBs-AS37_formulation 1 (Low dose) Group
Reporting group description: Participants received 2 doses of GSK's HBsAg candidate vaccine adjuvanted with GSK's AS37 adjuvant system formulation 1 (Low dose), at Day 1 and Day 31.	
Reporting group title	HBs-AS37_formulation 2 (High dose) Group
Reporting group description: Participants received 2 doses of GSK's HBsAg candidate vaccine adjuvanted with GSK's AS37 adjuvant system formulation 2 (High dose), at Day 1 and Day 31.	
Subject analysis set title	HBs-AS37_formulation 2 (Low dose) Group
Subject analysis set type	Per protocol
Subject analysis set description: Participants received 2 doses of GSK's HBsAg candidate vaccine adjuvanted with GSK's AS37 adjuvant system formulation 2 (Low dose), at Day 1 and Day 31.	
Subject analysis set title	HBs-AS37_formulation 2 Group
Subject analysis set type	Per protocol
Subject analysis set description: Participants received 2 doses of GSK's HBsAg candidate vaccine adjuvanted with GSK's AS37 adjuvant system formulation 2, at Day 1 and Day 31.	

Primary: Number of participants with solicited administration site adverse events (AEs) after dose 1

End point title	Number of participants with solicited administration site adverse events (AEs) after dose 1 ^[1]
End point description: Assessed solicited administration site events after vaccination included erythema, pain, and swelling at the injection site. Any = occurrence of the event regardless of intensity grade. The analysis was performed on the Exposed Set (ES), which included all participants who received at least 1 dose of the study intervention. Only participants with solicited administration site events diary card available after dose 1 administration for the specified duration were included in this analysis.	
End point type	Primary
End point timeframe: Day 1 (day of administration) to Day 14	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical hypothesis was tested.

End point values	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group	HBs-AS37_formulation 1 (Low dose) Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	25	25	24	25
Units: Participants				
Erythema	0	0	0	0
Pain	6	17	21	16
Swelling	0	0	0	0

End point values	HBs-AS37_formulation 2 (High dose) Group			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: Participants				
Erythema	0			
Pain	18			
Swelling	0			

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with solicited administration site AEs after dose 2

End point title	Number of participants with solicited administration site AEs after dose 2 ^[2]
End point description: Assessed solicited administration site events after vaccination included erythema, pain and swelling at the injection site. Any = occurrence of the event regardless of intensity grade. The analysis was performed on the ES. Only participants with solicited administration site events diary card available after dose 2 administration for the specified duration were included in this analysis.	
End point type	Primary
End point timeframe: Day 31 (day of administration) to Day 45	

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical hypothesis was tested.

End point values	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group	HBs-AS37_formulation 1 (Low dose) Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	24	24	23	25
Units: Participants				
Erythema	0	0	0	0
Pain	1	15	16	14

Swelling	0	0	0	0
----------	---	---	---	---

End point values	HBs-AS37_formulation 2 (High dose) Group			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: Participants				
Erythema	0			
Pain	14			
Swelling	0			

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with solicited systemic AEs after dose 1

End point title	Number of participants with solicited systemic AEs after dose
-----------------	---

End point description:

Assessed solicited systemic events included fever (defined as temperature greater than or equal to ($\geq$) 38.0°C regardless of the location of measurement), fatigue, myalgia, arthralgia, headache, chills, malaise, loss of appetite, nausea, vomiting, and diarrhea. The analysis was performed on the ES. Only participants with solicited systemic events diary card available after dose 1 administration for the specified duration were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 (day of administration) to Day 14

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical hypothesis was tested.

End point values	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group	HBs-AS37_formulation 1 (Low dose) Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	25	25	24	25
Units: Participants				
Arthralgia	1	2	2	2
Chills	2	0	0	1
Diarrhea	3	2	4	0
Fatigue	9	10	10	12
Headache	8	9	8	10
Loss of appetite	1	4	2	1
Malaise	8	2	7	3
Myalgia	8	6	14	7
Nausea	6	0	3	1

Fever	1	2	1	2
Vomiting	0	0	0	0

End point values	HBs-AS37_formulation 2 (High dose) Group			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: Participants				
Arthralgia	1			
Chills	1			
Diarrhea	2			
Fatigue	11			
Headache	10			
Loss of appetite	0			
Malaise	2			
Myalgia	9			
Nausea	1			
Fever	0			
Vomiting	0			

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with solicited systemic AEs after dose 2

End point title	Number of participants with solicited systemic AEs after dose
-----------------	---

End point description:

Assessed solicited systemic events included fever (defined as temperature $\geq 38.0^{\circ}\text{C}$ regardless of the location of measurement), fatigue, myalgia, arthralgia, headache, chills, malaise, loss of appetite, nausea, vomiting, and diarrhea. The analysis was performed on the ES. Only participants with solicited systemic events diary card available after dose 2 administration for the specified duration were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

Day 31 (day of administration) to Day 45

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical hypothesis was tested.

End point values	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group	HBs-AS37_formulation 1 (Low dose) Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	24	24	23	25
Units: Participants				

Arthralgia	2	3	1	1
Chills	2	4	0	1
Diarrhea	3	2	1	1
Fatigue	9	8	8	7
Headache	9	8	7	7
Loss of appetite	3	2	0	0
Malaise	6	7	1	3
Myalgia	2	7	12	6
Nausea	2	1	3	1
Fever	1	1	1	1
Vomiting	0	0	0	1

End point values	HBs-AS37_formulation 2 (High dose) Group			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: Participants				
Arthralgia	1			
Chills	2			
Diarrhea	1			
Fatigue	5			
Headache	4			
Loss of appetite	1			
Malaise	2			
Myalgia	7			
Nausea	2			
Fever	1			
Vomiting	1			

Statistical analyses

No statistical analyses for this end point

Primary: Duration in days of solicited administration site AEs after dose 1

End point title	Duration in days of solicited administration site AEs after dose 1 ^[5]
-----------------	---

End point description:

Duration is the number of days in which a participant experienced the symptom within the 14-day solicited follow-up period. The only solicited administration site event presented is pain. The analysis was performed on the ES. Only participants who experienced solicited administration site events after dose 1 administration for the specified duration were included in this analysis. Here, 'Number of Participants Analyzed' = participants with available data for solicited administration site events at dose 1. 99999= no data available.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 (day of administration) to Day 14

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical hypothesis was tested.

End point values	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group	HBs-AS37_formulation 1 (Low dose) Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	17	21	16
Units: Days				
median (inter-quartile range (Q1-Q3))	1.0 (1.0 to 1.0)	1.0 (1.0 to 3.0)	3.0 (1.0 to 4.0)	2.0 (1.0 to 3.0)

End point values	HBs-AS37_formulation 2 (High dose) Group			
Subject group type	Reporting group			
Number of subjects analysed	18			
Units: Days				
median (inter-quartile range (Q1-Q3))	1.0 (1.0 to 2.0)			

Statistical analyses

No statistical analyses for this end point

Primary: Duration in days of solicited administration site AEs after dose 2

End point title	Duration in days of solicited administration site AEs after dose 2 ^[6]
-----------------	---

End point description:

Duration is the number of days in which a participant experienced the symptom within the 14-day solicited follow-up period. The only solicited administration site event presented is pain. The analysis was performed on the ES. Only participants who experienced solicited administration site events after dose 2 administration for the specified duration were included in this analysis. Here, 'Number of Participants Analyzed' = participants with available data for solicited administration site events at dose 2.

End point type	Primary
----------------	---------

End point timeframe:

Day 31 (day of administration) to Day 45

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical hypothesis was tested.

End point values	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group	HBs-AS37_formulation 1 (Low dose) Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	15	16	14
Units: Days				
median (inter-quartile range (Q1-Q3))	1.0 (1.0 to 1.0)	2.0 (2.0 to 3.0)	4.0 (2.5 to 5.0)	1.5 (1.0 to 3.0)

End point values	HBs-AS37_formulation 2 (High dose) Group			
Subject group type	Reporting group			
Number of subjects analysed	14			
Units: Days				
median (inter-quartile range (Q1-Q3))	2.0 (1.0 to 3.0)			

Statistical analyses

No statistical analyses for this end point

Primary: Duration in days of solicited systemic AEs after dose 1

End point title	Duration in days of solicited systemic AEs after dose 1 ^[7]
-----------------	--

End point description:

Duration is the number of days in which a participant experienced the symptom within the 14-day solicited follow-up period. The analysis was performed on the ES. Only participants who experienced solicited systemic events after dose 1 administration for the specified duration were included in this analysis. Here, 'Number of Participants Analyzed' = participants with available data for solicited systemic events at dose 1. 99999= no data available.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 (day of administration) to Day 14

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical hypothesis was tested.

End point values	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group	HBs-AS37_formulation 1 (Low dose) Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	10	14	12
Units: Days				
median (inter-quartile range (Q1-Q3))				
Arthralgia (N=1,2,2,2,1)	2.0 (2.0 to 2.0)	1.5 (1.0 to 2.0)	1.0 (1.0 to 1.0)	2.0 (1.0 to 3.0)
Chills (N=2,0,0,1,1)	1.5 (1.0 to 2.0)	99999 (99999 to 99999)	99999 (99999 to 99999)	1.0 (1.0 to 1.0)
Diarrhea (N=3,2,4,0,2)	1.0 (1.0 to 3.0)	1.0 (1.0 to 1.0)	1.5 (1.0 to 2.0)	99999 (99999 to 99999)

Fatigue (N=9,10,10,12,11)	1.0 (1.0 to 3.0)	2.0 (1.0 to 4.0)	1.0 (1.0 to 3.0)	1.0 (1.0 to 2.0)
Headache (N=8,9,8,10,10)	1.0 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.5 (1.0 to 2.0)	1.0 (1.0 to 2.0)
Loss of appetite (N=1,4,2,1,0)	5.0 (5.0 to 5.0)	1.5 (1.0 to 2.0)	1.5 (1.0 to 2.0)	4.0 (4.0 to 4.0)
Malaise (N=8,2,7,3,2)	1.0 (1.0 to 2.0)	1.5 (1.0 to 2.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 3.0)
Myalgia (N=8,6,14,7,9)	1.5 (1.0 to 2.0)	1.0 (1.0 to 2.0)	2.0 (1.0 to 4.0)	1.0 (1.0 to 2.0)
Nausea (6,0,3,1,1)	1.0 (1.0 to 2.0)	99999 (99999 to 99999)	1.0 (1.0 to 1.0)	1.0 (1.0 to 1.0)
Fever (N=1,2,1,2,0)	1.0 (1.0 to 1.0)	2.5 (2.0 to 3.0)	3.0 (3.0 to 3.0)	3.0 (2.0 to 4.0)

End point values	HBs-AS37 formulation 2 (High dose) Group			
Subject group type	Reporting group			
Number of subjects analysed	11			
Units: Days				
median (inter-quartile range (Q1-Q3))				
Arthralgia (N=1,2,2,2,1)	1.0 (1.0 to 1.0)			
Chills (N=2,0,0,1,1)	3.0 (3.0 to 3.0)			
Diarrhea (N=3,2,4,0,2)	1.0 (1.0 to 1.0)			
Fatigue (N=9,10,10,12,11)	2.0 (1.0 to 2.0)			
Headache (N=8,9,8,10,10)	1.0 (1.0 to 1.0)			
Loss of appetite (N=1,4,2,1,0)	99999 (99999 to 99999)			
Malaise (N=8,2,7,3,2)	1.0 (1.0 to 1.0)			
Myalgia (N=8,6,14,7,9)	2.0 (1.0 to 2.0)			
Nausea (6,0,3,1,1)	1.0 (1.0 to 1.0)			
Fever (N=1,2,1,2,0)	99999 (99999 to 99999)			

Statistical analyses

No statistical analyses for this end point

Primary: Duration in days of solicited systemic AEs after dose 2

End point title	Duration in days of solicited systemic AEs after dose 2 ^[8]
-----------------	--

End point description:

Duration is the number of days in which a participant experienced the symptom within the 14-day solicited follow-up period. The analysis was performed on the ES. Only participants who experienced solicited systemic events after dose 2 administration for the specified duration were included in this analysis. Here, 'Number of Participants Analyzed' = participants with available data for solicited systemic events at dose 2.

End point type	Primary
----------------	---------

End point timeframe:

Day 31 (day of administration) to Day 45

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical hypothesis was tested.

End point values	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group	HBs-AS37_formulation 1 (Low dose) Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9	8	12	7
Units: Days				
median (inter-quartile range (Q1-Q3))				
Arthralgia (N=2,3,1,1,1)	2.0 (1.0 to 3.0)	1.0 (1.0 to 2.0)	1.0 (1.0 to 1.0)	5.0 (5.0 to 5.0)
Chills (N=2,4,0,1,2)	1.0 (1.0 to 1.0)	1.0 (1.0 to 1.5)	99999 (99999 to 99999)	1.0 (1.0 to 1.0)
Diarrhea (N=3,2,1,1,1)	1.0 (1.0 to 2.0)	1.5 (1.0 to 2.0)	2.0 (2.0 to 2.0)	2.0 (2.0 to 2.0)
Fatigue (N=9,8,8,7,5)	2.0 (1.0 to 3.0)	2.0 (1.0 to 3.5)	1.5 (1.0 to 4.0)	2.0 (1.0 to 3.0)
Headache (N=9,8,7,7,4)	1.0 (1.0 to 1.0)	1.5 (1.0 to 2.5)	1.0 (1.0 to 2.0)	1.0 (1.0 to 4.0)
Loss of appetite (N=3,2,0,0,1)	1.0 (1.0 to 5.0)	2.0 (1.0 to 3.0)	99999 (99999 to 99999)	99999 (99999 to 99999)
Malaise (N=6,7,1,3,2)	2.5 (2.0 to 3.0)	1.0 (1.0 to 2.0)	3.0 (3.0 to 3.0)	2.0 (1.0 to 6.0)
Myalgia (N=2,7,12,6,7)	2.5 (1.0 to 4.0)	2.0 (1.0 to 4.0)	2.5 (1.5 to 3.5)	2.0 (1.0 to 3.0)
Nausea (N=2,1,3,1,2)	2.5 (2.0 to 3.0)	1.0 (1.0 to 1.0)	1.0 (1.0 to 1.0)	2.0 (2.0 to 2.0)
Fever (N=1,1,1,1,1)	1.0 (1.0 to 1.0)	1.0 (1.0 to 1.0)	4.0 (4.0 to 4.0)	1.0 (1.0 to 1.0)
Vomiting (N=0,0,0,1,1)	99999 (99999 to 99999)	99999 (99999 to 99999)	99999 (99999 to 99999)	1.0 (1.0 to 1.0)

End point values	HBs-AS37_formulation 2 (High dose) Group			
Subject group type	Reporting group			
Number of subjects analysed	7			
Units: Days				
median (inter-quartile range (Q1-Q3))				
Arthralgia (N=2,3,1,1,1)	1.0 (1.0 to 1.0)			
Chills (N=2,4,0,1,2)	1.5 (1.0 to 2.0)			
Diarrhea (N=3,2,1,1,1)	1.0 (1.0 to 1.0)			
Fatigue (N=9,8,8,7,5)	1.0 (1.0 to 1.0)			
Headache (N=9,8,7,7,4)	2.0 (1.0 to 3.5)			
Loss of appetite (N=3,2,0,0,1)	1.0 (1.0 to 1.0)			
Malaise (N=6,7,1,3,2)	1.5 (1.0 to 2.0)			
Myalgia (N=2,7,12,6,7)	1.0 (1.0 to 3.0)			
Nausea (N=2,1,3,1,2)	1.0 (1.0 to 1.0)			
Fever (N=1,1,1,1,1)	2.0 (2.0 to 2.0)			
Vomiting (N=0,0,0,1,1)	2.0 (2.0 to 2.0)			

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with any unsolicited AEs after dose 1

End point title	Number of participants with any unsolicited AEs after dose 1 ^[9]
-----------------	---

End point description:

An unsolicited AE is an AE that was not included in a list of solicited events using a Participant Diary. Unsolicited events must have been spontaneously communicated by a participant who has signed the informed consent. Unsolicited AEs include both serious and non-serious AEs. Any = occurrence of the event regardless of intensity grade or relation to the study vaccination. The analysis was performed on the ES. Only participants with unsolicited AEs after dose 1 administration for the specified duration were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

Day 1 (day of administration) to Day 31

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical hypothesis was tested.

End point values	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group	HBs-AS37_formulation 1 (Low dose) Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	25	25	24	25
Units: Participants	7	2	6	4

End point values	HBs-AS37_formulation 2 (High dose) Group			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: Participants	5			

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with any unsolicited AEs after dose 2

End point title	Number of participants with any unsolicited AEs after dose 2 ^[10]
-----------------	--

End point description:

Any = occurrence of the event regardless of intensity grade or relation to the study vaccination. The analysis was performed on the ES. Only participants with unsolicited AEs after dose 2 administration for the specified duration were included in this analysis.

End point type	Primary
----------------	---------

End point timeframe:

Day 31 (day of administration) to Day 61

Notes:

[10] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical hypothesis was tested.

End point values	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group	HBs-AS37_formulation 1 (Low dose) Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	24	24	23	25
Units: Participants	5	7	6	6

End point values	HBs-AS37_formulation 2 (High dose) Group			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: Participants	6			

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with serious AEs (SAEs)

End point title	Number of participants with serious AEs (SAEs) ^[11]
-----------------	--

End point description:

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, or is an abnormal pregnancy outcome. Any = occurrence of the SAE regardless of intensity grade or relation to the study vaccination. The analysis was performed on the ES.

End point type	Primary
----------------	---------

End point timeframe:

Throughout the entire study period (from Day 1 to Day 361)

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical hypothesis was tested.

End point values	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group	HBs-AS37_formulation 1 (Low dose) Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	25	25	24	25
Units: Participants	0	0	0	1

End point values	HBs-AS37_formulation 2 (High dose) Group			
------------------	--	--	--	--

Subject group type	Reporting group			
Number of subjects analysed	23			
Units: Participants	0			

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with medically attended AEs (MAEs)

End point title	Number of participants with medically attended AEs (MAEs) ^[12]
-----------------	---

End point description:

An MAE is any AE with medically attended visits that were not routine visits for physical examination or vaccination, such as visits for hospitalization, an emergency room visit, or an otherwise unscheduled visit to or from medical personnel (medical doctor) for any reason. Any = occurrence of the MAE regardless of intensity grade or relation to the study vaccination. The analysis was performed on the ES.

End point type	Primary
----------------	---------

End point timeframe:

Throughout the entire study period (from Day 1 to Day 361)

Notes:

[12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical hypothesis was tested.

End point values	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group	HBs-AS37_formulation 1 (Low dose) Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	25	25	24	25
Units: Participants	8	2	2	3

End point values	HBs-AS37_formulation 2 (High dose) Group			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: Participants	4			

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with AEs leading to study withdrawal

End point title	Number of participants with AEs leading to study withdrawal ^[13]
-----------------	---

End point description:

An AE is any untoward medical occurrence (an unfavourable/unintended sign - including an abnormal

laboratory finding), symptom, or disease (new or exacerbated) in a clinical study participant that is temporally associated with the study intervention. The AE may or may not be considered related to the study intervention. A participant is considered to have withdrawn from the study if no new study procedure has been performed or no new information has been collected for him/her since the date of withdrawal/last contact. The analysis was performed on the ES.

End point type	Primary
----------------	---------

End point timeframe:

Throughout the entire study period (from Day 1 to Day 361)

Notes:

[13] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical hypothesis was tested.

End point values	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group	HBs-AS37_formulation 1 (Low dose) Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	25	25	24	25
Units: Participants	0	0	0	0

End point values	HBs-AS37_formulation 2 (High dose) Group			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: Participants	0			

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with potential mediated immune diseases (pIMDs)

End point title	Number of participants with potential mediated immune diseases (pIMDs) ^[14]
-----------------	--

End point description:

pIMDs are a subset of adverse events that include autoimmune diseases and other inflammatory and/or neurological disorders of interest which may or may not have an autoimmune aetiology. Any = occurrence of the pIMD regardless of intensity grade or relation to the study vaccination. The analysis was performed on the ES.

End point type	Primary
----------------	---------

End point timeframe:

Throughout the entire study period (from Day 1 to Day 361)

Notes:

[14] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical hypothesis was tested.

End point values	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group	HBs-AS37_formulation 1 (Low dose) Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	25	25	24	25
Units: Participants	0	0	0	1

End point values	HBs-AS37_formulation 2 (High dose) Group			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: Participants	0			

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with abnormal hematology and biochemistry laboratory parameter values at Day 1

End point title	Number of participants with abnormal hematology and biochemistry laboratory parameter values at Day 1 ^[15]
-----------------	---

End point description:

In the analysis were included biochemistry parameters: ALT, AST, bicarbonate, blood urea nitrogen, chloride, C reactive protein, creatinine, potassium, sodium; and hematology parameters: eosinophils, erythrocytes, hemoglobin, lymphocytes, platelets, monocytes, neutrophils, WBC. Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. The analysis was performed on the ES. Only participants for whom the specified laboratory data were available for the specified duration were included in analysis.

End point type	Primary
----------------	---------

End point timeframe:

At Day 1 (baseline)

Notes:

[15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical hypothesis was tested.

End point values	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group	HBs-AS37_formulation 1 (Low dose) Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	25	25	24	25
Units: Participants				
ALT Below (N=25,25,24,25,23)	0	0	0	0
AST Below (N=25,25,24,25,23)	0	0	0	0
Bicarbonate, Day 1 Below (N=25,25,24,25,23)	0	0	0	0

Blood urea nitrogen Below (N=25,25,24,25,23)	0	0	0	0
Chloride Below (N=25,25,24,25,23)	0	0	0	0
C Reactive Protein Below (N=25,25,24,25,23)	0	0	0	0
Creatinine Below (N=25,25,24,25,23)	0	0	0	0
Potassium Below (N=25,25,24,25,23)	0	0	1	0
Sodium Below (N=25,25,24,25,23)	0	0	0	1
Eosinophils Below (N=25,25,24,25,23)	1	1	1	3
Erythrocytes Below (N=25,25,24,25,23)	1	1	3	2
Hemoglobin Below (N=25,25,24,25,23)	3	0	5	3
Lymphocytes Below (N=25,25,24,25,23)	0	0	0	0
Platelets Below (N=25,25,24,25,23)	0	0	0	0
Monocytes Below (N=25,25,24,25,23)	0	0	0	0
Neutrophils Below (N=25,25,24,25,23)	1	1	2	1
WBC Below (N=24,25,24,25,23)	3	1	1	0
ALT Within (N=25,25,24,25,23)	21	21	23	23
AST Within (N=25,25,24,25,23)	22	24	24	25
Bicarbonate, Day 1 Within (N=25,25,24,25,23)	25	25	24	25
Blood urea nitrogen Within (N=25,25,24,25,23)	24	23	22	24
Chloride Within (N=25,25,24,25,23)	25	24	24	25
C Reactive Protein Within (N=25,25,24,25,23)	24	24	21	23
Creatinine Within (N=25,25,24,25,23)	24	22	22	23
Potassium Within (N=25,25,24,25,23)	25	25	23	25
Sodium Within (N=25,25,24,25,23)	25	25	24	24
Eosinophils Within (N=25,25,24,25,23)	24	23	22	21
Erythrocytes Within (N=25,25,24,25,23)	24	24	21	22
Hemoglobin Within (N=25,25,24,25,23)	22	25	19	22
Lymphocytes Within (N=25,25,24,25,23)	25	25	24	25
Platelets Within (N=25,25,24,25,23)	25	24	22	25
Monocytes Within (N=25,25,24,25,23)	25	25	24	25
Neutrophils Within (N=25,25,24,25,23)	24	24	22	24
WBC Within (N=24,25,24,25,23)	21	23	23	24
ALT Above (N=25,25,24,25,23)	4	4	1	2
AST Above (N=25,25,24,25,23)	3	1	0	0
Bicarbonate, Day 1 Above (N=25,25,24,25,23)	0	0	0	0
Blood urea nitrogen Above (N=25,25,24,25,23)	1	2	2	1
Chloride Above (N=25,25,24,25,23)	0	1	0	0
C Reactive Protein Above (N=25,25,24,25,23)	1	1	3	2
Creatinine Above (N=25,25,24,25,23)	1	3	2	2
Potassium Above (N=25,25,24,25,23)	0	0	0	0
Sodium Above (N=25,25,24,25,23)	0	0	0	0
Eosinophils Above (N=25,25,24,25,23)	0	1	1	1
Erythrocytes Above (N=25,25,24,25,23)	0	0	0	1
Hemoglobin Above (N=25,25,24,25,23)	0	0	0	0
Lymphocytes Above (N=25,25,24,25,23)	0	0	0	0

Platelets Above (N=25,25,24,25,23)	0	1	2	0
Monocytes Above (N=25,25,24,25,23)	0	0	0	0
Neutrophils Above (N=25,25,24,25,23)	0	0	0	0
WBC Above (N=24,25,24,25,23)	0	1	0	1
ALT Missing (N=25,25,24,25,23)	0	0	0	0
AST Missing (N=25,25,24,25,23)	0	0	0	0
Bicarbonate, Day 1 Missing (N=25,25,24,25,23)	0	0	0	0
Blood urea nitrogen Missing (N=25,25,24,25,23)	0	0	0	0
Chloride Missing (N=25,25,24,25,23)	0	0	0	0
C Reactive Protein Missing (N=25,25,24,25,23)	0	0	0	0
Creatinine Missing (N=25,25,24,25,23)	0	0	0	0
Potassium Missing (N=25,25,24,25,23)	0	0	0	0
Sodium Missing (N=25,25,24,25,23)	0	0	0	0
Eosinophils Missing (N=25,25,24,25,23)	0	0	0	0
Erythrocytes Missing (N=25,25,24,25,23)	0	0	0	0
Hemoglobin Missing (N=25,25,24,25,23)	0	0	0	0
Lymphocytes Missing (N=25,25,24,25,23)	0	0	0	0
Platelets Missing (N=25,25,24,25,23)	0	0	0	0
Monocytes Missing (N=25,25,24,25,23)	0	0	0	0
Neutrophils Missing (N=25,25,24,25,23)	0	0	0	0
WBC Missing (N=24,25,24,25,23)	0	0	0	0

End point values	HBs- AS37_formulation on 2 (High dose) Group			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: Participants				
ALT Below (N=25,25,24,25,23)	0			
AST Below (N=25,25,24,25,23)	0			
Bicarbonate, Day 1 Below (N=25,25,24,25,23)	1			
Blood urea nitrogen Below (N=25,25,24,25,23)	0			
Chloride Below (N=25,25,24,25,23)	0			
C Reactive Protein Below (N=25,25,24,25,23)	0			
Creatinine Below (N=25,25,24,25,23)	0			
Potassium Below (N=25,25,24,25,23)	0			
Sodium Below (N=25,25,24,25,23)	0			
Eosinophils Below (N=25,25,24,25,23)	2			
Erythrocytes Below (N=25,25,24,25,23)	1			
Hemoglobin Below (N=25,25,24,25,23)	3			
Lymphocytes Below (N=25,25,24,25,23)	0			
Platelets Below (N=25,25,24,25,23)	0			

Monocytes Below (N=25,25,24,25,23)	1			
Neutrophils Below (N=25,25,24,25,23)	1			
WBC Below (N=24,25,24,25,23)	1			
ALT Within (N=25,25,24,25,23)	21			
AST Within (N=25,25,24,25,23)	22			
Bicarbonate, Day 1 Within (N=25,25,24,25,23)	22			
Blood urea nitrogen Within (N=25,25,24,25,23)	23			
Chloride Within (N=25,25,24,25,23)	23			
C Reactive Protein Within (N=25,25,24,25,23)	20			
Creatinine Within (N=25,25,24,25,23)	23			
Potassium Within (N=25,25,24,25,23)	23			
Sodium Within (N=25,25,24,25,23)	23			
Eosinophils Within (N=25,25,24,25,23)	21			
Erythrocytes Within (N=25,25,24,25,23)	22			
Hemoglobin Within (N=25,25,24,25,23)	20			
Lymphocytes Within (N=25,25,24,25,23)	23			
Platelets Within (N=25,25,24,25,23)	23			
Monocytes Within (N=25,25,24,25,23)	22			
Neutrophils Within (N=25,25,24,25,23)	22			
WBC Within (N=24,25,24,25,23)	22			
ALT Above (N=25,25,24,25,23)	2			
AST Above (N=25,25,24,25,23)	1			
Bicarbonate, Day 1 Above (N=25,25,24,25,23)	0			
Blood urea nitrogen Above (N=25,25,24,25,23)	0			
Chloride Above (N=25,25,24,25,23)	0			
C Reactive Protein Above (N=25,25,24,25,23)	3			
Creatinine Above (N=25,25,24,25,23)	0			
Potassium Above (N=25,25,24,25,23)	0			
Sodium Above (N=25,25,24,25,23)	0			
Eosinophils Above (N=25,25,24,25,23)	0			
Erythrocytes Above (N=25,25,24,25,23)	0			
Hemoglobin Above (N=25,25,24,25,23)	0			
Lymphocytes Above (N=25,25,24,25,23)	0			
Platelets Above (N=25,25,24,25,23)	0			
Monocytes Above (N=25,25,24,25,23)	0			
Neutrophils Above (N=25,25,24,25,23)	0			
WBC Above (N=24,25,24,25,23)	0			
ALT Missing (N=25,25,24,25,23)	0			
AST Missing (N=25,25,24,25,23)	0			
Bicarbonate, Day 1 Missing (N=25,25,24,25,23)	0			
Blood urea nitrogen Missing (N=25,25,24,25,23)	0			
Chloride Missing (N=25,25,24,25,23)	0			
C Reactive Protein Missing (N=25,25,24,25,23)	0			
Creatinine Missing (N=25,25,24,25,23)	0			

Potassium Missing (N=25,25,24,25,23)	0			
Sodium Missing (N=25,25,24,25,23)	0			
Eosinophils Missing (N=25,25,24,25,23)	0			
Erythrocytes Missing (N=25,25,24,25,23)	0			
Hemoglobin Missing (N=25,25,24,25,23)	0			
Lymphocytes Missing (N=25,25,24,25,23)	0			
Platelets Missing (N=25,25,24,25,23)	0			
Monocytes Missing (N=25,25,24,25,23)	0			
Neutrophils Missing (N=25,25,24,25,23)	0			
WBC Missing (N=24,25,24,25,23)	0			

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with abnormal hematology and biochemistry laboratory parameter values at Day 8

End point title	Number of participants with abnormal hematology and biochemistry laboratory parameter values at Day 8 ^[16]
-----------------	---

End point description:

In the analysis were included biochemistry parameters: alanine aminotransferase (ALT), aspartate transaminase (AST), bicarbonate, blood urea nitrogen, chloride, C reactive protein, creatinine, potassium, sodium; and hematology parameters: eosinophils, erythrocytes, hemoglobin, lymphocytes, platelets, monocytes, neutrophils, white blood cells (WBC). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. The analysis was performed on the ES. Only participants for whom the specified laboratory data were available for the specified duration were included in analysis.

End point type	Primary
----------------	---------

End point timeframe:

At Day 8

Notes:

[16] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical hypothesis was tested.

End point values	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group	HBs-AS37 formulation 1 (Low dose) Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	25	25	24	25
Units: Participants				
ALT Below (N=25,25,24,25,23)	0	0	0	0
AST Below (N=25,25,24,25,23)	0	0	0	0
Bicarbonate Below (N=25,25,24,25,23)	0	0	0	0
Blood urea nitrogen Below (N=25,25,24,25,23)	0	0	0	0
Chloride Below (N=25,25,24,25,23)	0	0	0	0
C Reactive Protein Below (N=25,25,24,25,23)	0	0	0	0

Creatinine Below (N=25,25,24,25,23)	0	0	0	0
Potassium Below (N=25,25,24,25,23)	0	0	0	0
Sodium Below (N=25,25,24,25,23)	0	0	0	0
Eosinophils Below (N=25,25,24,25,23)	2	0	1	2
Erythrocytes Below (N=25,25,24,25,23)	1	0	2	1
Hemoglobin Below (N=25,25,24,25,23)	4	0	5	1
Lymphocytes Below (N=25,25,24,25,23)	0	0	0	0
Platelets Below (N=25,25,24,25,23)	0	0	0	0
Monocytes Below (N=25,25,24,25,23)	0	0	0	0
Neutrophils Below (N=25,25,24,25,23)	1	1	1	0
WBC Below (N=24,25,24,25,23)	1	1	1	0
ALT Within (N=25,25,24,25,23)	23	22	22	22
AST Within (N=25,25,24,25,23)	24	24	24	24
Bicarbonate Within (N=25,25,24,25,23)	24	25	24	25
Blood urea nitrogen Within (N=25,25,24,25,23)	25	22	23	25
Chloride Within (N=25,25,24,25,23)	25	25	23	25
C Reactive Protein Within (N=25,25,24,25,23)	23	24	21	24
Creatinine Within (N=25,25,24,25,23)	23	23	24	24
Potassium Within (N=25,25,24,25,23)	24	25	23	24
Sodium Within (N=25,25,24,25,23)	25	25	24	25
Eosinophils Within (N=25,25,24,25,23)	22	24	23	21
Erythrocytes Within (N=25,25,24,25,23)	23	25	22	23
Hemoglobin Within (N=25,25,24,25,23)	20	25	19	24
Lymphocytes Within (N=25,25,24,25,23)	24	25	24	24
Platelets Within (N=25,25,24,25,23)	24	23	22	25
Monocytes Within (N=25,25,24,25,23)	24	25	24	24
Neutrophils Within (N=25,25,24,25,23)	23	24	22	24
WBC Within (N=24,25,24,25,23)	22	24	23	24
ALT Above (N=25,25,24,25,23)	2	3	2	3
AST Above (N=25,25,24,25,23)	1	1	0	1
Bicarbonate Above (N=25,25,24,25,23)	1	0	0	0
Blood urea nitrogen Above (N=25,25,24,25,23)	0	3	1	0
Chloride Above (N=25,25,24,25,23)	0	0	1	0
C Reactive Protein Above (N=25,25,24,25,23)	2	1	3	1
Creatinine Above (N=25,25,24,25,23)	2	2	0	1
Potassium Above (N=25,25,24,25,23)	1	0	1	1
Sodium Above (N=25,25,24,25,23)	0	0	0	0
Eosinophils Above (N=25,25,24,25,23)	0	1	0	1
Erythrocytes Above (N=25,25,24,25,23)	0	0	0	1
Hemoglobin Above (N=25,25,24,25,23)	0	0	0	0
Lymphocytes Above (N=25,25,24,25,23)	0	0	0	0
Platelets Above (N=25,25,24,25,23)	0	2	1	0
Monocytes Above (N=25,25,24,25,23)	0	0	0	0
Neutrophils Above (N=25,25,24,25,23)	0	0	1	0
WBC Above (N=24,25,24,25,23)	1	0	0	1
ALT Missing (N=25,25,24,25,23)	0	0	0	0

AST Missing (N=25,25,24,25,23)	0	0	0	0
Bicarbonate Missing (N=25,25,24,25,23)	0	0	0	0
Blood urea nitrogen Missing (N=25,25,24,25,23)	0	0	0	0
Chloride Missing (N=25,25,24,25,23)	0	0	0	0
C Reactive Protein Missing (N=25,25,24,25,23)	0	0	0	0
Creatinine Missing (N=25,25,24,25,23)	0	0	0	0
Potassium Missing (N=25,25,24,25,23)	0	0	0	0
Sodium Missing (N=25,25,24,25,23)	0	0	0	0
Eosinophils Missing (N=25,25,24,25,23)	1	0	0	1
Erythrocytes Missing (N=25,25,24,25,23)	1	0	0	0
Hemoglobin Missing (N=25,25,24,25,23)	1	0	0	0
Lymphocytes Missing (N=25,25,24,25,23)	1	0	0	1
Platelets Missing (N=25,25,24,25,23)	1	0	1	0
Monocytes Missing (N=25,25,24,25,23)	1	0	0	1
Neutrophils Missing (N=25,25,24,25,23)	1	0	0	1
WBC Missing (N=24,25,24,25,23)	0	0	0	0

End point values	HBs-AS37_formulation 2 (High dose) Group			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: Participants				
ALT Below (N=25,25,24,25,23)	0			
AST Below (N=25,25,24,25,23)	0			
Bicarbonate Below (N=25,25,24,25,23)	0			
Blood urea nitrogen Below (N=25,25,24,25,23)	0			
Chloride Below (N=25,25,24,25,23)	1			
C Reactive Protein Below (N=25,25,24,25,23)	0			
Creatinine Below (N=25,25,24,25,23)	0			
Potassium Below (N=25,25,24,25,23)	0			
Sodium Below (N=25,25,24,25,23)	1			
Eosinophils Below (N=25,25,24,25,23)	2			
Erythrocytes Below (N=25,25,24,25,23)	1			
Hemoglobin Below (N=25,25,24,25,23)	3			
Lymphocytes Below (N=25,25,24,25,23)	0			
Platelets Below (N=25,25,24,25,23)	0			
Monocytes Below (N=25,25,24,25,23)	0			
Neutrophils Below (N=25,25,24,25,23)	1			
WBC Below (N=24,25,24,25,23)	1			
ALT Within (N=25,25,24,25,23)	21			
AST Within (N=25,25,24,25,23)	23			
Bicarbonate Within (N=25,25,24,25,23)	23			

Blood urea nitrogen Within (N=25,25,24,25,23)	22			
Chloride Within (N=25,25,24,25,23)	22			
C Reactive Protein Within (N=25,25,24,25,23)	21			
Creatinine Within (N=25,25,24,25,23)	20			
Potassium Within (N=25,25,24,25,23)	23			
Sodium Within (N=25,25,24,25,23)	22			
Eosinophils Within (N=25,25,24,25,23)	19			
Erythrocytes Within (N=25,25,24,25,23)	21			
Hemoglobin Within (N=25,25,24,25,23)	19			
Lymphocytes Within (N=25,25,24,25,23)	22			
Platelets Within (N=25,25,24,25,23)	22			
Monocytes Within (N=25,25,24,25,23)	22			
Neutrophils Within (N=25,25,24,25,23)	21			
WBC Within (N=24,25,24,25,23)	20			
ALT Above (N=25,25,24,25,23)	2			
AST Above (N=25,25,24,25,23)	0			
Bicarbonate Above (N=25,25,24,25,23)	0			
Blood urea nitrogen Above (N=25,25,24,25,23)	1			
Chloride Above (N=25,25,24,25,23)	0			
C Reactive Protein Above (N=25,25,24,25,23)	2			
Creatinine Above (N=25,25,24,25,23)	3			
Potassium Above (N=25,25,24,25,23)	0			
Sodium Above (N=25,25,24,25,23)	0			
Eosinophils Above (N=25,25,24,25,23)	1			
Erythrocytes Above (N=25,25,24,25,23)	0			
Hemoglobin Above (N=25,25,24,25,23)	0			
Lymphocytes Above (N=25,25,24,25,23)	0			
Platelets Above (N=25,25,24,25,23)	0			
Monocytes Above (N=25,25,24,25,23)	0			
Neutrophils Above (N=25,25,24,25,23)	0			
WBC Above (N=24,25,24,25,23)	1			
ALT Missing (N=25,25,24,25,23)	0			
AST Missing (N=25,25,24,25,23)	0			
Bicarbonate Missing (N=25,25,24,25,23)	0			
Blood urea nitrogen Missing (N=25,25,24,25,23)	0			
Chloride Missing (N=25,25,24,25,23)	0			
C Reactive Protein Missing (N=25,25,24,25,23)	0			
Creatinine Missing (N=25,25,24,25,23)	0			
Potassium Missing (N=25,25,24,25,23)	0			
Sodium Missing (N=25,25,24,25,23)	0			
Eosinophils Missing (N=25,25,24,25,23)	1			
Erythrocytes Missing (N=25,25,24,25,23)	1			
Hemoglobin Missing (N=25,25,24,25,23)	1			

Lymphocytes Missing (N=25,25,24,25,23)	1			
Platelets Missing (N=25,25,24,25,23)	1			
Monocytes Missing (N=25,25,24,25,23)	1			
Neutrophils Missing (N=25,25,24,25,23)	1			
WBC Missing (N=24,25,24,25,23)	1			

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with abnormal hematology and biochemistry laboratory parameter values at Day 31

End point title	Number of participants with abnormal hematology and biochemistry laboratory parameter values at Day 31 ^[17]
-----------------	--

End point description:

In the analysis were included biochemistry parameters: alanine aminotransferase (ALT), aspartate transaminase (AST), bicarbonate, blood urea nitrogen, chloride, C reactive protein, creatinine, potassium, sodium; and hematology parameters: eosinophils, erythrocytes, hemoglobin, lymphocytes, platelets, monocytes, neutrophils, white blood cells (WBC). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. The analysis was performed on the ES. Only participants for whom the specified laboratory data were available for the specified duration were included in analysis.

End point type	Primary
----------------	---------

End point timeframe:

At Day 31

Notes:

[17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical hypothesis was tested.

End point values	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group	HBs-AS37_formulation 1 (Low dose) Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	24	24	23	25
Units: Participants				
ALT Below	0	0	0	0
AST Below	0	0	0	0
Bicarbonate Below	0	0	0	0
Blood urea nitrogen Below	0	0	0	0
Chloride Below	0	0	0	0
C Reactive Protein Below	0	0	0	0
Creatinine Below	0	0	0	0
Potassium Below	0	1	0	1
Sodium Below	0	1	1	0
Eosinophils Below	0	0	1	2
Erythrocytes Below	0	1	5	1
Hemoglobin Below	3	1	5	2
Lymphocytes Below	0	0	0	0

Platelets Below	0	0	0	0
Monocytes Below	1	0	0	0
Neutrophils Below	0	1	0	1
WBC Below	1	1	0	1
ALT Within	19	19	22	21
AST Within	22	23	21	24
Bicarbonate Within	24	24	23	24
Blood urea nitrogen Within	23	21	22	23
Chloride Within	24	24	23	23
C Reactive Protein Within	22	23	17	25
Creatinine Within	24	22	23	22
Potassium Within	24	23	23	22
Sodium Within	24	23	22	24
Eosinophils Within	23	23	22	21
Erythrocytes Within	24	23	18	23
Hemoglobin Within	21	23	17	22
Lymphocytes Within	24	24	23	24
Platelets Within	23	23	22	24
Monocytes Within	23	24	23	24
Neutrophils Within	24	23	23	23
WBC Within	22	22	23	22
ALT Above	5	5	1	3
AST Above	2	1	2	0
Bicarbonate Above	0	0	0	0
Blood urea nitrogen Above	1	3	1	1
Chloride Above	0	0	0	1
C Reactive Protein Above	2	1	6	0
Creatinine Above	0	2	0	2
Potassium Above	0	0	0	1
Sodium Above	0	0	0	0
Eosinophils Above	1	1	0	1
Erythrocytes Above	0	0	0	0
Hemoglobin Above	0	0	1	0
Lymphocytes Above	0	0	0	0
Platelets Above	1	1	1	0
Monocytes Above	0	0	0	0
Neutrophils Above	0	0	0	0
WBC Above	1	1	0	1
ALT Missing	0	0	0	1
AST Missing	0	0	0	1
Bicarbonate Missing	0	0	0	1
Blood urea nitrogen Missing	0	0	0	1
Chloride Missing	0	0	0	1
C Reactive Protein Missing	0	0	0	0
Creatinine Missing	0	0	0	1
Potassium Missing	0	0	0	1
Sodium Missing	0	0	0	1
Eosinophils Missing	0	0	0	1
Erythrocytes Missing	0	0	0	1
Hemoglobin Missing	0	0	0	1
Lymphocytes Missing	0	0	0	1
Platelets Missing	0	0	0	1

Monocytes Missing	0	0	0	1
Neutrophils Missing	0	0	0	1
WBC Missing	0	0	0	1

End point values	HBs- AS37_formulation 2 (High dose) Group			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: Participants				
ALT Below	0			
AST Below	0			
Bicarbonate Below	0			
Blood urea nitrogen Below	0			
Chloride Below	0			
C Reactive Protein Below	0			
Creatinine Below	0			
Potassium Below	0			
Sodium Below	2			
Eosinophils Below	1			
Erythrocytes Below	2			
Hemoglobin Below	4			
Lymphocytes Below	0			
Platelets Below	0			
Monocytes Below	0			
Neutrophils Below	1			
WBC Below	1			
ALT Within	22			
AST Within	23			
Bicarbonate Within	23			
Blood urea nitrogen Within	20			
Chloride Within	22			
C Reactive Protein Within	20			
Creatinine Within	22			
Potassium Within	23			
Sodium Within	21			
Eosinophils Within	22			
Erythrocytes Within	21			
Hemoglobin Within	19			
Lymphocytes Within	23			
Platelets Within	22			
Monocytes Within	23			
Neutrophils Within	20			
WBC Within	21			
ALT Above	1			
AST Above	0			
Bicarbonate Above	0			
Blood urea nitrogen Above	3			
Chloride Above	1			

C Reactive Protein Above	3			
Creatinine Above	1			
Potassium Above	0			
Sodium Above	0			
Eosinophils Above	0			
Erythrocytes Above	0			
Hemoglobin Above	0			
Lymphocytes Above	0			
Platelets Above	1			
Monocytes Above	0			
Neutrophils Above	2			
WBC Above	1			
ALT Missing	0			
AST Missing	0			
Bicarbonate Missing	0			
Blood urea nitrogen Missing	0			
Chloride Missing	0			
C Reactive Protein Missing	0			
Creatinine Missing	0			
Potassium Missing	0			
Sodium Missing	0			
Eosinophils Missing	0			
Erythrocytes Missing	0			
Hemoglobin Missing	0			
Lymphocytes Missing	0			
Platelets Missing	0			
Monocytes Missing	0			
Neutrophils Missing	0			
WBC Missing	0			

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with abnormal hematology and biochemistry laboratory parameter values at Day 38

End point title	Number of participants with abnormal hematology and biochemistry laboratory parameter values at Day 38 ^[18]
-----------------	--

End point description:

In the analysis were included biochemistry parameters: alanine aminotransferase (ALT), aspartate transaminase (AST), bicarbonate, blood urea nitrogen, chloride, C reactive protein, creatinine, potassium, sodium; and hematology parameters: eosinophils, erythrocytes, hemoglobin, lymphocytes, platelets, monocytes, neutrophils, white blood cells (WBC). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. The analysis was performed on the ES. Only participants for whom the specified laboratory data were available for the specified duration were included in analysis.

End point type	Primary
----------------	---------

End point timeframe:

At Day 38

Notes:

[18] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical hypothesis was tested.

End point values	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group	HBs-AS37_formulation 1 (Low dose) Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	24	23	22	25
Units: Participants				
ALT Below	0	0	0	0
AST Below	0	0	0	0
Bicarbonate Below	1	0	1	0
Blood urea nitrogen Below	0	0	0	0
Chloride Below	0	0	0	0
C Reactive Protein Below	0	0	0	0
Creatinine Below	0	0	0	0
Potassium Below	0	0	1	0
Sodium Below	0	1	0	0
Eosinophils Below	0	1	0	0
Erythrocytes Below	1	0	1	1
Hemoglobin Below	3	1	6	2
Lymphocytes Below	0	1	0	0
Platelets Below	0	0	0	0
Monocytes Below	0	0	0	0
Neutrophils Below	3	2	0	1
WBC Below	3	2	0	0
ALT Within	19	21	20	23
AST Within	22	22	22	24
Bicarbonate Within	21	22	21	25
Blood urea nitrogen Within	23	22	20	24
Chloride Within	22	23	22	25
C Reactive Protein Within	19	20	17	24
Creatinine Within	22	21	21	25
Potassium Within	23	23	20	25
Sodium Within	23	22	22	25
Eosinophils Within	21	21	22	24
Erythrocytes Within	22	23	21	23
Hemoglobin Within	20	22	16	23
Lymphocytes Within	22	22	21	25
Platelets Within	23	23	20	25
Monocytes Within	22	23	21	25
Neutrophils Within	18	19	22	23
WBC Within	19	19	21	24
ALT Above	4	2	2	2
AST Above	1	1	0	1
Bicarbonate Above	1	1	0	0
Blood urea nitrogen Above	0	1	2	1
Chloride Above	1	0	0	0
C Reactive Protein Above	4	3	5	1
Creatinine Above	1	2	1	0

Potassium Above	0	0	1	0
Sodium Above	0	0	0	0
Eosinophils Above	1	1	0	1
Erythrocytes Above	0	0	0	1
Hemoglobin Above	0	0	0	0
Lymphocytes Above	0	0	1	0
Platelets Above	0	0	2	0
Monocytes Above	0	0	1	0
Neutrophils Above	1	2	0	1
WBC Above	1	2	1	1
ALT Missing	1	0	0	0
AST Missing	1	0	0	0
Bicarbonate Missing	1	0	0	0
Blood urea nitrogen Missing	1	0	0	0
Chloride Missing	1	0	0	0
C Reactive Protein Missing	1	0	0	0
Creatinine Missing	1	0	0	0
Potassium Missing	1	0	0	0
Sodium Missing	1	0	0	0
Eosinophils Missing	2	0	0	0
Erythrocytes Missing	1	0	0	0
Hemoglobin Missing	1	0	0	0
Lymphocytes Missing	2	0	0	0
Platelets Missing	1	0	0	0
Monocytes Missing	2	0	0	0
Neutrophils Missing	2	0	0	0
WBC Missing	1	0	0	0

End point values	HBs- AS37_formulation 2 (High dose) Group			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: Participants				
ALT Below	0			
AST Below	0			
Bicarbonate Below	1			
Blood urea nitrogen Below	0			
Chloride Below	1			
C Reactive Protein Below	0			
Creatinine Below	0			
Potassium Below	0			
Sodium Below	1			
Eosinophils Below	1			
Erythrocytes Below	1			
Hemoglobin Below	5			
Lymphocytes Below	1			
Platelets Below	0			
Monocytes Below	0			

Neutrophils Below	0			
WBC Below	0			
ALT Within	22			
AST Within	23			
Bicarbonate Within	21			
Blood urea nitrogen Within	22			
Chloride Within	22			
C Reactive Protein Within	21			
Creatinine Within	21			
Potassium Within	22			
Sodium Within	22			
Eosinophils Within	22			
Erythrocytes Within	22			
Hemoglobin Within	18			
Lymphocytes Within	22			
Platelets Within	22			
Monocytes Within	23			
Neutrophils Within	23			
WBC Within	23			
ALT Above	1			
AST Above	0			
Bicarbonate Above	1			
Blood urea nitrogen Above	1			
Chloride Above	0			
C Reactive Protein Above	2			
Creatinine Above	2			
Potassium Above	1			
Sodium Above	0			
Eosinophils Above	0			
Erythrocytes Above	0			
Hemoglobin Above	0			
Lymphocytes Above	0			
Platelets Above	1			
Monocytes Above	0			
Neutrophils Above	0			
WBC Above	0			
ALT Missing	0			
AST Missing	0			
Bicarbonate Missing	0			
Blood urea nitrogen Missing	0			
Chloride Missing	0			
C Reactive Protein Missing	0			
Creatinine Missing	0			
Potassium Missing	0			
Sodium Missing	0			
Eosinophils Missing	0			
Erythrocytes Missing	0			
Hemoglobin Missing	0			
Lymphocytes Missing	0			
Platelets Missing	0			
Monocytes Missing	0			
Neutrophils Missing	0			

WBC Missing	0			
-------------	---	--	--	--

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with abnormal hematology and biochemistry laboratory parameter values at Day 61

End point title	Number of participants with abnormal hematology and biochemistry laboratory parameter values at Day 61 ^[19]
-----------------	--

End point description:

In the analysis were included biochemistry parameters: alanine aminotransferase (ALT), aspartate transaminase (AST), bicarbonate, blood urea nitrogen, chloride, C reactive protein, creatinine, potassium, sodium; and hematology parameters: eosinophils, erythrocytes, hemoglobin, lymphocytes, platelets, monocytes, neutrophils, white blood cells (WBC). Below = value below the laboratory reference range defined for the specified visit and laboratory parameter; Within = value within the laboratory reference range defined for the specified visit and laboratory parameter; Above = value above the laboratory reference range defined for the specified visit and laboratory parameter. The analysis was performed on the ES. Only participants for whom the specified laboratory data were available for the specified duration were included in analysis.

End point type	Primary
----------------	---------

End point timeframe:

At Day 61

Notes:

[19] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical hypothesis was tested.

End point values	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group	HBs-AS37_formulation 1 (Low dose) Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	24	24	23	25
Units: Participants				
ALT Below (N=24,24,23,25,23)	0	0	0	0
AST Below (N=24,24,23,25,23)	0	0	0	0
Bicarbonate Below (N=24,24,23,25,23)	0	0	0	2
Blood urea nitrogen Below (N=24,24,23,25,23)	0	0	0	0
Chloride Below (N=24,24,23,25,23)	0	0	0	0
C Reactive Protein Below (N=24,24,23,25,23)	0	0	0	0
Creatinine Below (N=24,24,23,25,23)	0	0	0	0
Potassium Below (N=24,24,23,25,23)	0	0	1	0
Sodium Below (N=24,24,23,25,23)	0	0	0	0
Eosinophils Below (N=24,24,23,25,23)	0	0	1	0
Erythrocytes Below (N=24,24,23,25,23)	1	1	4	3
Hemoglobin Below (N=24,24,23,25,23)	4	1	5	4
Lymphocytes Below (N=23,24,23,25,23)	0	0	0	0
Platelets Below (N=24,24,23,25,23)	0	0	0	0

Monocytes Below (N=23,24,23,25,23)	0	0	0	1
Neutrophils Below (N=23,24,23,25,23)	0	0	1	2
WBC Below (N=24,24,23,25,23)	1	2	0	1
ALT Within (N=24,24,23,25,23)	21	20	21	23
AST Within (N=24,24,23,25,23)	21	21	22	24
Bicarbonate Within (N=24,24,23,25,23)	24	23	23	23
Blood urea nitrogen Within (N=24,24,23,25,23)	23	22	21	25
Chloride Within (N=24,24,23,25,23)	24	23	22	25
C Reactive Protein Within (N=24,24,23,25,23)	20	21	17	24
Creatinine Within (N=24,24,23,25,23)	23	21	22	24
Potassium Within (N=24,24,23,25,23)	23	21	22	24
Sodium Within (N=24,24,23,25,23)	24	23	23	25
Eosinophils Within (N=24,24,23,25,23)	21	23	22	24
Erythrocytes Within (N=24,24,23,25,23)	22	23	19	21
Hemoglobin Within (N=24,24,23,25,23)	19	23	18	21
Lymphocytes Within (N=23,24,23,25,23)	23	24	23	25
Platelets Within (N=24,24,23,25,23)	22	22	21	24
Monocytes Within (N=23,24,23,25,23)	23	24	23	24
Neutrophils Within (N=23,24,23,25,23)	21	23	22	22
WBC Within (N=24,24,23,25,23)	20	21	23	22
ALT Above (N=24,24,23,25,23)	3	4	2	2
AST Above (N=24,24,23,25,23)	3	3	1	1
Bicarbonate Above (N=24,24,23,25,23)	0	1	0	0
Blood urea nitrogen Above (N=24,24,23,25,23)	1	2	2	0
Chloride Above (N=24,24,23,25,23)	0	1	1	0
C Reactive Protein Above (N=24,24,23,25,23)	4	3	5	1
Creatinine Above (N=24,24,23,25,23)	1	3	1	1
Potassium Above (N=24,24,23,25,23)	1	3	0	1
Sodium Above (N=24,24,23,25,23)	0	1	0	0
Eosinophils Above (N=24,24,23,25,23)	1	1	0	1
Erythrocytes Above (N=24,24,23,25,23)	0	0	0	1
Hemoglobin Above (N=24,24,23,25,23)	0	0	0	0
Lymphocytes Above (N=23,24,23,25,23)	0	0	0	0
Platelets Above (N=24,24,23,25,23)	0	2	2	0
Monocytes Above (N=23,24,23,25,23)	0	0	0	0
Neutrophils Above (N=24,24,23,25,23)	2	1	0	1
WBC Above (N=24,24,23,25,23)	2	1	0	2
ALT Missing (N=24,24,23,25,23)	0	0	0	0
AST Missing (N=24,24,23,25,23)	0	0	0	0
Bicarbonate Missing (N=24,24,23,25,23)	0	0	0	0
Blood urea nitrogen Missing (N=24,24,23,25,23)	0	0	0	0
Chloride Missing (N=24,24,23,25,23)	0	0	0	0
C Reactive Protein Missing (N=24,24,23,25,23)	0	0	1	0
Creatinine Missing (N=24,24,23,25,23)	0	0	0	0
Potassium Missing (N=24,24,23,25,23)	0	0	0	0

Sodium Missing (N=24,24,23,25,23)	0	0	0	0
Eosinophils Missing (N=24,24,23,25,23)	2	0	0	0
Erythrocytes Missing (N=24,24,23,25,23)	1	0	0	0
Hemoglobin Missing (N=24,24,23,25,23)	1	0	0	0
Lymphocytes Missing (N=23,24,23,25,23)	0	0	0	0
Platelets Missing (N=24,24,23,25,23)	2	0	0	1
Monocytes Missing (N=23,24,23,25,23)	0	0	0	0
Neutrophils Missing (N=23,24,23,25,23)	0	0	0	0
WBC Missing (N=24,24,23,25,23)	1	0	0	0

End point values	HBs-AS37_formulation 2 (High dose) Group			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: Participants				
ALT Below (N=24,24,23,25,23)	0			
AST Below (N=24,24,23,25,23)	0			
Bicarbonate Below (N=24,24,23,25,23)	1			
Blood urea nitrogen Below (N=24,24,23,25,23)	0			
Chloride Below (N=24,24,23,25,23)	1			
C Reactive Protein Below (N=24,24,23,25,23)	0			
Creatinine Below (N=24,24,23,25,23)	0			
Potassium Below (N=24,24,23,25,23)	0			
Sodium Below (N=24,24,23,25,23)	2			
Eosinophils Below (N=24,24,23,25,23)	1			
Erythrocytes Below (N=24,24,23,25,23)	0			
Hemoglobin Below (N=24,24,23,25,23)	3			
Lymphocytes Below (N=23,24,23,25,23)	1			
Platelets Below (N=24,24,23,25,23)	0			
Monocytes Below (N=23,24,23,25,23)	0			
Neutrophils Below (N=23,24,23,25,23)	0			
WBC Below (N=24,24,23,25,23)	0			
ALT Within (N=24,24,23,25,23)	20			
AST Within (N=24,24,23,25,23)	22			
Bicarbonate Within (N=24,24,23,25,23)	22			
Blood urea nitrogen Within (N=24,24,23,25,23)	23			
Chloride Within (N=24,24,23,25,23)	22			
C Reactive Protein Within (N=24,24,23,25,23)	20			
Creatinine Within (N=24,24,23,25,23)	22			
Potassium Within (N=24,24,23,25,23)	23			
Sodium Within (N=24,24,23,25,23)	21			
Eosinophils Within (N=24,24,23,25,23)	22			

Erythrocytes Within (N=24,24,23,25,23)	23			
Hemoglobin Within (N=24,24,23,25,23)	20			
Lymphocytes Within (N=23,24,23,25,23)	22			
Platelets Within (N=24,24,23,25,23)	23			
Monocytes Within (N=23,24,23,25,23)	23			
Neutrophils Within (N=23,24,23,25,23)	23			
WBC Within (N=24,24,23,25,23)	22			
ALT Above (N=24,24,23,25,23)	3			
AST Above (N=24,24,23,25,23)	1			
Bicarbonate Above (N=24,24,23,25,23)	0			
Blood urea nitrogen Above (N=24,24,23,25,23)	0			
Chloride Above (N=24,24,23,25,23)	0			
C Reactive Protein Above (N=24,24,23,25,23)	3			
Creatinine Above (N=24,24,23,25,23)	1			
Potassium Above (N=24,24,23,25,23)	0			
Sodium Above (N=24,24,23,25,23)	0			
Eosinophils Above (N=24,24,23,25,23)	0			
Erythrocytes Above (N=24,24,23,25,23)	0			
Hemoglobin Above (N=24,24,23,25,23)	0			
Lymphocytes Above (N=23,24,23,25,23)	0			
Platelets Above (N=24,24,23,25,23)	0			
Monocytes Above (N=23,24,23,25,23)	0			
Neutrophils Above (N=24,24,23,25,23)	0			
WBC Above (N=24,24,23,25,23)	1			
ALT Missing (N=24,24,23,25,23)	0			
AST Missing (N=24,24,23,25,23)	0			
Bicarbonate Missing (N=24,24,23,25,23)	0			
Blood urea nitrogen Missing (N=24,24,23,25,23)	0			
Chloride Missing (N=24,24,23,25,23)	0			
C Reactive Protein Missing (N=24,24,23,25,23)	0			
Creatinine Missing (N=24,24,23,25,23)	0			
Potassium Missing (N=24,24,23,25,23)	0			
Sodium Missing (N=24,24,23,25,23)	0			
Eosinophils Missing (N=24,24,23,25,23)	0			
Erythrocytes Missing (N=24,24,23,25,23)	0			
Hemoglobin Missing (N=24,24,23,25,23)	0			
Lymphocytes Missing (N=23,24,23,25,23)	0			
Platelets Missing (N=24,24,23,25,23)	0			
Monocytes Missing (N=23,24,23,25,23)	0			
Neutrophils Missing (N=23,24,23,25,23)	0			
WBC Missing (N=24,24,23,25,23)	0			

Statistical analyses

No statistical analyses for this end point

Primary: Mean percent change from baseline (pre-vaccination, Day 1) in hematology and biochemistry parameters post-dose 1 (Day 8 relative to baseline [pre-vaccination Day 1])

End point title	Mean percent change from baseline (pre-vaccination, Day 1) in hematology and biochemistry parameters post-dose 1 (Day 8 relative to baseline [pre-vaccination Day 1])[20]
-----------------	---

End point description:

In the analysis were included biochemistry parameters: alanine aminotransferase (ALT), aspartate aminotransferase (AST), bicarbonate, blood urea nitrogen, chloride, C reactive protein, creatinine, potassium, sodium; and hematology parameters: eosinophils, erythrocytes, hemoglobin, lymphocytes, platelets, monocytes, neutrophils, white blood cells (WBC). The analysis was performed on the ES. Only participants for whom the specified laboratory data after dose 1 administration were available for the specified duration were included in analysis.

End point type	Primary
----------------	---------

End point timeframe:

At Day 8 (relative to baseline [pre-vaccination Day 1])

Notes:

[20] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical hypothesis was tested.

End point values	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group	HBs-AS37_formulation 1 (Low dose) Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	25	25	24	25
Units: Mean percent change from baseline				
arithmetic mean (standard deviation)				
ALT (N=25,25,24,25,23)	-3.04 (± 20.322)	-6.69 (± 14.117)	-1.13 (± 34.221)	8.14 (± 25.853)
AST (N=25,25,24,25,23)	4.74 (± 17.106)	-5.62 (± 14.509)	-1.79 (± 18.626)	7.35 (± 24.486)
Bicarbonate (N=25,25,24,25,23)	0.52 (± 7.789)	-0.19 (± 8.276)	3.68 (± 8.491)	0.06 (± 10.180)
Blood urea nitrogen (N=25,25,24,25,23)	2.60 (± 29.717)	-3.03 (± 19.264)	1.84 (± 32.456)	0.09 (± 25.501)
Chloride (N=25,25,24,25,23)	0.79 (± 1.921)	0.23 (± 2.119)	-0.11 (± 2.000)	-0.33 (± 2.247)
C Reactive Protein (N=25,25,24,25,23)	78.43 (± 349.570)	41.16 (± 124.844)	129.65 (± 393.365)	5.72 (± 57.451)
Creatinine (N=25,25,24,25,23)	0.34 (± 8.164)	-2.35 (± 10.278)	-2.01 (± 7.209)	-0.10 (± 9.989)
Potassium (N=25,25,24,25,23)	1.88 (± 8.648)	-0.14 (± 8.133)	1.91 (± 8.313)	2.43 (± 7.932)
Sodium (N=25,25,24,25,23)	0.26 (± 1.204)	0.18 (± 1.376)	0.27 (± 1.438)	0.04 (± 1.481)
Eosinophils (N=24,25,24,24,22)	20.35 (± 45.285)	31.51 (± 76.423)	-3.33 (± 46.839)	18.15 (± 45.276)
Erythrocytes (N=24,25,24,25,22)	-2.06 (± 3.756)	-1.01 (± 3.786)	-0.67 (± 4.423)	0.45 (± 5.160)
Hemoglobin (N=24,25,24,25,22)	-2.17 (± 3.729)	-0.94 (± 3.817)	-0.60 (± 3.892)	0.74 (± 5.156)
Lymphocytes (N=24,25,24,25,22)	8.79 (± 18.849)	6.58 (± 23.996)	1.25 (± 25.224)	7.80 (± 32.898)

Platelets (N=24,25,24,25,22)	1.56 (± 10.141)	2.84 (± 7.234)	5.10 (± 10.605)	4.72 (± 10.952)
Monocytes (N=24,25,24,25,22)	8.83 (± 23.264)	6.20 (± 24.148)	7.31 (± 36.121)	12.52 (± 35.758)
Neutrophils (N=24,25,24,25,22)	2.69 (± 27.341)	-2.23 (± 28.410)	14.24 (± 38.460)	2.03 (± 25.842)
WBC (N=24,25,24,25,22)	4.06 (± 16.847)	0.88 (± 17.754)	7.58 (± 19.074)	0.26 (± 21.314)

End point values	HBs-AS37_formulation 2 (High dose) Group			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: Mean percent change from baseline				
arithmetic mean (standard deviation)				
ALT (N=25,25,24,25,23)	0.95 (± 15.926)			
AST (N=25,25,24,25,23)	2.28 (± 16.477)			
Bicarbonate (N=25,25,24,25,23)	4.16 (± 7.337)			
Blood urea nitrogen (N=25,25,24,25,23)	-0.63 (± 15.543)			
Chloride (N=25,25,24,25,23)	-0.24 (± 2.119)			
C Reactive Protein (N=25,25,24,25,23)	-6.50 (± 45.671)			
Creatinine (N=25,25,24,25,23)	0.76 (± 9.176)			
Potassium (N=25,25,24,25,23)	0.27 (± 6.323)			
Sodium (N=25,25,24,25,23)	0.19 (± 1.253)			
Eosinophils (N=24,25,24,24,22)	12.86 (± 38.767)			
Erythrocytes (N=24,25,24,25,22)	-0.21 (± 4.384)			
Hemoglobin (N=24,25,24,25,22)	-0.36 (± 4.075)			
Lymphocytes (N=24,25,24,25,22)	4.04 (± 15.252)			
Platelets (N=24,25,24,25,22)	5.67 (± 11.517)			
Monocytes (N=24,25,24,25,22)	4.98 (± 24.417)			
Neutrophils (N=24,25,24,25,22)	4.70 (± 28.444)			
WBC (N=24,25,24,25,22)	3.53 (± 18.126)			

Statistical analyses

No statistical analyses for this end point

Primary: Mean percent change from baseline (pre-vaccination, Day 1) in hematology and biochemistry parameters post-dose 1 (Day 31 compared with baseline [pre-vaccination, Day 1])

End point title	Mean percent change from baseline (pre-vaccination, Day 1) in hematology and biochemistry parameters post-dose 1 (Day 31 compared with baseline [pre-vaccination, Day 1]) ^[21]
-----------------	---

End point description:

In the analysis were included biochemistry parameters: ALT, AST, bicarbonate, blood urea nitrogen, chloride, C reactive protein, creatinine, potassium, sodium; and hematology parameters: eosinophils, erythrocytes, hemoglobin, lymphocytes, platelets, monocytes, neutrophils, WBC. The analysis was performed on the ES. Only participants for whom the specified laboratory data after dose 1 administration were available for the specified duration were included in analysis.

End point type	Primary
----------------	---------

End point timeframe:

At Day 31 (compared with baseline [pre-vaccination, Day 1])

Notes:

[21] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical hypothesis was tested.

End point values	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group	HBs-AS37_formulation 1 (Low dose) Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	24	24	23	25
Units: Mean percent change from baseline				
arithmetic mean (standard deviation)				
ALT (N=24,24,23,24,23)	-2.45 (± 32.837)	12.52 (± 81.650)	2.94 (± 25.235)	5.89 (± 25.561)
AST (N=24,24,23,24,23)	-0.60 (± 22.151)	0.12 (± 25.394)	3.33 (± 31.456)	3.21 (± 22.040)
Bicarbonate (N=24,24,23,24,23)	0.58 (± 11.020)	-2.47 (± 9.490)	0.78 (± 10.526)	-0.20 (± 9.834)
Blood urea nitrogen (N=24,24,23,24,23)	-1.04 (± 17.638)	1.42 (± 23.387)	-5.65 (± 27.995)	-3.27 (± 27.699)
Chloride (N=24,24,23,24,23)	0.76 (± 2.430)	0.29 (± 2.668)	-0.16 (± 1.836)	0.09 (± 2.059)
C Reactive Protein (N=24,24,23,24,23)	23.07 (± 94.084)	37.95 (± 143.597)	130.90 (± 518.895)	12.48 (± 63.081)
Creatinine (N=24,24,23,24,23)	-3.73 (± 8.529)	-4.69 (± 9.817)	-1.37 (± 7.374)	-1.77 (± 9.931)
Potassium (N=24,24,23,24,23)	-1.60 (± 6.867)	0.23 (± 7.493)	-0.78 (± 7.674)	2.46 (± 8.750)
Sodium (N=24,24,23,24,23)	0.18 (± 1.273)	0.49 (± 1.486)	-0.28 (± 1.113)	0.31 (± 1.221)
Eosinophils (N=24,24,23,24,23)	61.95 (± 156.721)	10.80 (± 47.476)	6.13 (± 42.536)	43.03 (± 99.613)
Erythrocytes (N=24,24,23,24,23)	-2.30 (± 3.813)	-0.71 (± 3.877)	-1.14 (± 5.730)	0.76 (± 4.317)
Hemoglobin (N=24,24,23,24,23)	-1.99 (± 4.925)	-0.25 (± 3.795)	-0.75 (± 5.168)	0.92 (± 4.328)
Lymphocytes (N=24,24,23,24,23)	3.44 (± 15.877)	5.02 (± 23.147)	4.16 (± 24.245)	-0.47 (± 22.632)
Platelets (N=24,24,23,24,23)	-4.21 (± 10.893)	-1.86 (± 13.771)	1.72 (± 10.562)	2.92 (± 9.752)
Monocytes (N=24,24,23,24,23)	8.76 (± 44.115)	9.84 (± 30.487)	5.31 (± 30.151)	7.75 (± 34.218)

Neutrophils (N=24,24,23,24,23)	10.63 (± 43.055)	2.47 (± 29.935)	8.26 (± 27.070)	-0.67 (± 24.740)
WBC (N=24,24,23,24,23)	6.65 (± 26.757)	2.37 (± 18.732)	5.78 (± 20.170)	-2.04 (± 18.832)

End point values	HBs-AS37_formulation 2 (High dose) Group			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: Mean percent change from baseline				
arithmetic mean (standard deviation)				
ALT (N=24,24,23,24,23)	3.07 (± 27.915)			
AST (N=24,24,23,24,23)	4.57 (± 21.930)			
Bicarbonate (N=24,24,23,24,23)	4.65 (± 12.535)			
Blood urea nitrogen (N=24,24,23,24,23)	3.70 (± 23.551)			
Chloride (N=24,24,23,24,23)	0.17 (± 2.022)			
C Reactive Protein (N=24,24,23,24,23)	77.00 (± 358.139)			
Creatinine (N=24,24,23,24,23)	-2.23 (± 9.222)			
Potassium (N=24,24,23,24,23)	-1.54 (± 6.611)			
Sodium (N=24,24,23,24,23)	0.13 (± 1.318)			
Eosinophils (N=24,24,23,24,23)	0.88 (± 44.640)			
Erythrocytes (N=24,24,23,24,23)	-1.06 (± 5.496)			
Hemoglobin (N=24,24,23,24,23)	-1.06 (± 4.325)			
Lymphocytes (N=24,24,23,24,23)	0.61 (± 17.722)			
Platelets (N=24,24,23,24,23)	0.68 (± 10.344)			
Monocytes (N=24,24,23,24,23)	9.96 (± 29.752)			
Neutrophils (N=24,24,23,24,23)	12.13 (± 32.091)			
WBC (N=24,24,23,24,23)	6.17 (± 19.512)			

Statistical analyses

No statistical analyses for this end point

Primary: Mean percent change from baseline (pre-vaccination, Day 1) in hematology and biochemistry parameters post-dose 2 (Day 38 compared with baseline [pre-vaccination, Day 1])

End point title	Mean percent change from baseline (pre-vaccination, Day 1) in hematology and biochemistry parameters post-dose 2 (Day 38 compared with baseline [pre-vaccination, Day 1])[²²]
-----------------	--

End point description:

In the analysis were included biochemistry parameters: ALT, AST, bicarbonate, blood urea nitrogen, chloride, C reactive protein, creatinine, potassium, sodium; and hematology parameters: eosinophils, erythrocytes, hemoglobin, lymphocytes, platelets, monocytes, neutrophils, WBC. The analysis was performed on the ES. Only participants for whom the specified laboratory data after dose 2 administration were available for the specified duration were included in analysis.

End point type	Primary
----------------	---------

End point timeframe:

At Day 38 (compared with baseline [pre-vaccination, Day 1])

Notes:

[22] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical hypothesis was tested.

End point values	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group	HBs-AS37_formulation 1 (Low dose) Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	23	23	22	25
Units: Mean percent change from baseline				
arithmetic mean (standard deviation)				
ALT (N=23,23,22,25,23)	-1.70 (± 28.091)	-9.56 (± 28.152)	8.70 (± 40.893)	7.81 (± 24.159)
AST(N=23,23,22,25,23)	1.91 (± 26.199)	-7.81 (± 21.151)	11.34 (± 41.922)	5.63 (± 17.430)
Bicarbonate(N=23,23,22,25,23)	-0.10 (± 11.002)	1.04 (± 7.590)	4.41 (± 12.016)	0.75 (± 9.389)
Blood urea nitrogen(N=23,23,22,25,23)	2.83 (± 30.148)	-1.73 (± 23.632)	2.30 (± 39.154)	0.69 (± 28.712)
Chloride(N=23,23,22,25,23)	0.39 (± 1.824)	-0.18 (± 2.413)	-0.96 (± 2.079)	-0.46 (± 2.004)
C Reactive Protein(N=23,23,22,25,23)	57.03 (± 191.211)	131.87 (± 475.577)	55.41 (± 110.350)	146.04 (± 584.663)
Creatinine (N=23,23,22,25,23)	1.18 (± 10.007)	-2.71 (± 8.546)	-0.25 (± 7.389)	0.61 (± 11.670)
Potassium (N=23,23,22,25,23)	-0.11 (± 8.188)	0.30 (± 10.244)	1.76 (± 10.350)	1.83 (± 8.246)
Sodium (N=23,23,22,25,23)	0.31 (± 0.802)	0.32 (± 1.833)	-0.03 (± 1.268)	0.01 (± 1.225)
Eosinophils (N=23,23,22,25,23)	103.21 (± 216.663)	64.45 (± 142.771)	27.38 (± 65.060)	35.67 (± 96.666)
Erythrocytes (N=23,23,22,25,23)	-2.59 (± 4.677)	-0.54 (± 3.879)	0.01 (± 5.660)	0.66 (± 4.466)
Hemoglobin (N=23,23,22,25,23)	-1.89 (± 5.602)	-0.44 (± 3.530)	-0.05 (± 5.064)	0.88 (± 4.548)
Lymphocytes (N=22,23,22,25,23)	2.35 (± 22.056)	8.61 (± 23.233)	15.80 (± 31.316)	2.46 (± 25.691)
Platelets (N=23,23,22,25,23)	1.41 (± 11.656)	5.25 (± 14.869)	6.56 (± 11.374)	2.33 (± 10.113)
Monocytes (N=22,23,22,25,23)	20.33 (± 52.053)	5.44 (± 29.929)	23.51 (± 31.162)	10.00 (± 32.556)
Neutrophils (N=22,23,22,25,23)	8.11 (± 39.675)	10.17 (± 55.015)	12.80 (± 27.430)	-5.36 (± 24.208)
WBC (N=23,23,22,25,23)	5.34 (± 24.916)	8.19 (± 34.765)	12.42 (± 18.141)	-3.72 (± 16.095)

End point values	HBs-AS37 formulation 2 (High dose) Group			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: Mean percent change from baseline				
arithmetic mean (standard deviation)				
ALT (N=23,23,22,25,23)	-4.15 (± 19.568)			
AST(N=23,23,22,25,23)	-2.19 (± 18.087)			
Bicarbonate(N=23,23,22,25,23)	5.04 (± 11.085)			
Blood urea nitrogen(N=23,23,22,25,23)	5.34 (± 23.796)			
Chloride(N=23,23,22,25,23)	0.39 (± 2.058)			
C Reactive Protein(N=23,23,22,25,23)	3.02 (± 66.364)			
Creatinine (N=23,23,22,25,23)	1.40 (± 9.723)			
Potassium (N=23,23,22,25,23)	2.15 (± 7.425)			
Sodium (N=23,23,22,25,23)	0.38 (± 1.128)			
Eosinophils (N=23,23,22,25,23)	6.21 (± 58.498)			
Erythrocytes (N=23,23,22,25,23)	-1.46 (± 5.741)			
Hemoglobin (N=23,23,22,25,23)	-2.32 (± 3.201)			
Lymphocytes (N=22,23,22,25,23)	0.10 (± 23.742)			
Platelets (N=23,23,22,25,23)	3.02 (± 14.577)			
Monocytes (N=22,23,22,25,23)	10.95 (± 42.691)			
Neutrophils (N=22,23,22,25,23)	-3.26 (± 32.341)			
WBC (N=23,23,22,25,23)	-3.79 (± 19.528)			

Statistical analyses

No statistical analyses for this end point

Primary: Mean percent change from baseline (pre-vaccination, Day 1) in hematology and biochemistry parameters post-dose 2 (Day 61 compared with baseline [pre-vaccination, Day 1])

End point title	Mean percent change from baseline (pre-vaccination, Day 1) in hematology and biochemistry parameters post-dose 2 (Day 61 compared with baseline [pre-vaccination, Day 1]) ^[23]
-----------------	---

End point description:

In the analysis were included biochemistry parameters: ALT, AST, bicarbonate, blood urea nitrogen,

chloride, C reactive protein, creatinine, potassium, sodium; and hematology parameters: eosinophils, erythrocytes, hemoglobin, lymphocytes, platelets, monocytes, neutrophils, WBC. The analysis was performed on the ES. Only participants for whom the specified laboratory data after dose 2 administration were available for the specified duration were included in analysis.

End point type	Primary
End point timeframe:	
At Day 61 (compared with baseline [pre-vaccination, Day 1])	

Notes:

[23] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: This endpoint was descriptive, hence no statistical hypothesis was tested.

End point values	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group	HBs-AS37 formulation 1 (Low dose) Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	24	24	23	25
Units: Mean percent change from baseline				
arithmetic mean (standard deviation)				
ALT (N=24,24,23,25,23)	-4.71 (± 27.145)	61.39 (± 318.144)	12.94 (± 49.927)	4.67 (± 36.939)
AST (N=24,24,23,25,23)	8.19 (± 43.555)	42.91 (± 171.398)	18.51 (± 68.383)	8.78 (± 47.643)
Bicarbonate (N=24,24,23,25,23)	0.66 (± 8.676)	-2.36 (± 8.453)	3.17 (± 9.880)	-3.21 (± 10.373)
Blood urea nitrogen (N=24,24,23,25,23)	8.26 (± 26.719)	-1.24 (± 32.101)	-4.94 (± 21.078)	-2.00 (± 25.429)
Chloride (N=24,24,23,25,23)	-0.22 (± 2.006)	0.48 (± 2.157)	0.09 (± 1.691)	-0.14 (± 2.311)
C Reactive Protein (N=24,24,23,25,23)	64.02 (± 180.495)	121.89 (± 432.514)	79.61 (± 218.741)	91.49 (± 237.304)
Creatinine (N=24,24,23,25,23)	2.96 (± 13.010)	-1.84 (± 13.034)	1.15 (± 11.041)	-3.95 (± 8.215)
Potassium (N=24,24,23,25,23)	0.33 (± 9.316)	3.34 (± 10.727)	-1.88 (± 7.115)	1.17 (± 8.379)
Sodium (N=24,24,23,25,23)	-0.35 (± 1.278)	0.34 (± 1.881)	0.44 (± 1.278)	-0.33 (± 1.156)
Eosinophils (N=23,24,23,25,23)	20.20 (± 32.608)	32.37 (± 59.533)	42.38 (± 91.920)	57.74 (± 144.539)
Erythrocytes (N=23,24,23,25,23)	-0.86 (± 5.037)	0.65 (± 5.327)	-0.76 (± 5.901)	0.51 (± 4.813)
Hemoglobin (N=23,24,23,25,23)	-0.86 (± 6.190)	0.49 (± 4.971)	-0.85 (± 5.363)	0.60 (± 4.671)
Lymphocytes (N=23,24,23,25,23)	6.43 (± 21.692)	2.32 (± 18.547)	9.74 (± 32.460)	-1.74 (± 27.336)
Platelets (N=22,24,23,25,23)	-1.29 (± 11.369)	2.12 (± 15.566)	1.35 (± 12.342)	3.77 (± 10.156)
Monocytes (N=23,24,23,25,23)	21.95 (± 56.206)	12.47 (± 32.131)	15.05 (± 30.852)	5.66 (± 35.371)
Neutrophils (N=23,24,23,25,23)	3.81 (± 33.133)	-6.10 (± 40.627)	8.68 (± 31.904)	4.91 (± 34.720)
WBC (N=23,24,23,25,23)	5.16 (± 22.729)	-3.20 (± 25.520)	9.32 (± 24.511)	0.84 (± 24.001)

End point values	HBs-			
------------------	------	--	--	--

	AS37_formulation 2 (High dose) Group			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: Mean percent change from baseline				
arithmetic mean (standard deviation)				
ALT (N=24,24,23,25,23)	13.83 (± 63.700)			
AST (N=24,24,23,25,23)	3.47 (± 33.308)			
Bicarbonate (N=24,24,23,25,23)	4.64 (± 12.554)			
Blood urea nitrogen (N=24,24,23,25,23)	2.60 (± 21.312)			
Chloride (N=24,24,23,25,23)	0.01 (± 1.803)			
C Reactive Protein (N=24,24,23,25,23)	109.50 (± 512.035)			
Creatinine (N=24,24,23,25,23)	-1.20 (± 7.048)			
Potassium (N=24,24,23,25,23)	-0.21 (± 6.832)			
Sodium (N=24,24,23,25,23)	0.25 (± 1.335)			
Eosinophils (N=23,24,23,25,23)	17.59 (± 63.368)			
Erythrocytes (N=23,24,23,25,23)	-0.63 (± 5.596)			
Hemoglobin (N=23,24,23,25,23)	-1.01 (± 3.466)			
Lymphocytes (N=23,24,23,25,23)	4.92 (± 21.356)			
Platelets (N=22,24,23,25,23)	3.47 (± 11.839)			
Monocytes (N=23,24,23,25,23)	15.01 (± 42.423)			
Neutrophils (N=23,24,23,25,23)	12.12 (± 42.077)			
WBC (N=23,24,23,25,23)	7.14 (± 25.180)			

Statistical analyses

No statistical analyses for this end point

Secondary: Geometric mean concentration (GMC) of anti-HBs antibody concentrations

End point title	Geometric mean concentration (GMC) of anti-HBs antibody concentrations
End point description:	
Anti-HBs antibody concentration was measured as GMC and expressed in milli international units per milliliter (mIU/mL). The analysis was performed on the Per-Protocol set (PPS), which included all participants who received all doses as per protocol, had immunogenicity results post-dose, complied with dosing/blood draw intervals, without intercurrent conditions that may interfere with immunogenicity and without prohibited concomitant medication/vaccination. Only participants with data available at the specified timepoints were included in the analysis.	
End point type	Secondary

End point timeframe:

At Day 1, Day 31, Day 61 and Day 361

End point values	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group	HBs-AS37_formulation 1 (Low dose) Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	25	24	23	24
Units: mIU/mL				
geometric mean (confidence interval 95%)				
Day 1 (N=25,24,23,24,23)	3.4 (3.0 to 3.8)	3.1 (3.1 to 3.1)	3.1 (3.1 to 3.1)	3.1 (3.1 to 3.1)
Day 31 (N=24,22,23,22,21)	7.7 (3.0 to 20.0)	204.9 (62.8 to 668.4)	8.3 (3.4 to 20.2)	22.0 (10.4 to 46.6)
Day 61 (N=24,21,24,22,21)	40.3 (14.3 to 113.1)	7193.0 (4062.5 to 12735.8)	86.3 (41.1 to 181.0)	401.3 (212.0 to 759.8)
Day 361 (N=21,19,22,20,23)	1055.9 (359.2 to 3103.7)	3211.8 (2252.4 to 4579.7)	41.4 (18.9 to 90.6)	153.2 (81.6 to 287.7)

End point values	HBs-AS37_formulation 2 (High dose) Group			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: mIU/mL				
geometric mean (confidence interval 95%)				
Day 1 (N=25,24,23,24,23)	3.1 (3.1 to 3.1)			
Day 31 (N=24,22,23,22,21)	95.2 (27.6 to 327.5)			
Day 61 (N=24,21,24,22,21)	1574.2 (600.6 to 4125.7)			
Day 361 (N=21,19,22,20,23)	586.3 (242.2 to 1419.4)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants who seroconverted for anti-HBs

End point title	Percentage of participants who seroconverted for anti-HBs
-----------------	---

End point description:

A participant who seroconverted for anti-HBs is defined as a participant with an anti-HBs antibody concentration higher than (>) 6.2 mIU/mL. The analysis was performed on the PPS. Only participants with data available at the specified timepoints were included in the analysis.

End point type	Secondary
End point timeframe:	
At Day 31, Day 61 and Day 361	

End point values	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group	HBs-AS37 formulation 1 (Low dose) Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	24	22	23	22
Units: Percentage of participants				
number (confidence interval 95%)				
Day 31 (N=24,22,23,22,21)	16.7 (4.7 to 37.4)	95.5 (77.2 to 99.9)	21.7 (7.5 to 43.7)	59.1 (36.4 to 79.3)
Day 61 (N=24,21,23,22,21)	75.0 (53.3 to 90.2)	100 (83.9 to 100)	87.0 (66.4 to 97.2)	100 (84.6 to 100)
Day 361 (N=21,19,22,20,23)	95.2 (76.2 to 99.9)	100 (82.4 to 100)	72.7 (49.8 to 89.3)	100 (83.2 to 100)

End point values	HBs-AS37 formulation 2 (High dose) Group			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: Percentage of participants				
number (confidence interval 95%)				
Day 31 (N=24,22,23,22,21)	81.0 (58.1 to 94.6)			
Day 61 (N=24,21,23,22,21)	100 (83.9 to 100)			
Day 361 (N=21,19,22,20,23)	100 (85.2 to 100)			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants seroprotected for anti-HBs

End point title	Percentage of participants seroprotected for anti-HBs
End point description:	
A participant seroprotected for anti-HBs is defined as a participant with an anti-HBs antibody concentration >10 mIU/mL. The analysis was performed on the PPS. Only participants with data available at the specified timepoints were included in the analysis.	
End point type	Secondary
End point timeframe:	
At Day 31, Day 61 and Day 361	

End point values	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group	HBs- AS37_formulati on 1 (Low dose) Group
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	24	22	23	22
Units: Percentage of participants				
number (confidence interval 95%)				
Day 31 (N=24,22,23,22,21)	16.7 (4.7 to 37.4)	95.5 (77.2 to 99.9)	21.7 (7.5 to 43.7)	59.1 (36.4 to 79.3)
Day 61 (N=24,21,23,22,21)	62.5 (40.6 to 81.2)	100 (83.9 to 100)	87.0 (66.4 to 97.2)	100 (84.6 to 100)
Day 361 (N=21,19,22,20,23)	95.2 (76.2 to 99.9)	100 (82.4 to 100)	72.7 (49.8 to 89.3)	100 (83.2 to 100)

End point values	HBs- AS37_formulati on 2 (High dose) Group			
Subject group type	Reporting group			
Number of subjects analysed	23			
Units: Percentage of participants				
number (confidence interval 95%)				
Day 31 (N=24,22,23,22,21)	81.0 (58.1 to 94.6)			
Day 61 (N=24,21,23,22,21)	100 (83.9 to 100)			
Day 361 (N=21,19,22,20,23)	100 (85.2 to 100)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Solicited AEs: within 14 days after any vaccination. Unsolicited AEs: within 31 days after any vaccination. All-cause mortality, SAEs, MAEs, AEs leading to withdrawal and pIMDs: from first vaccination (Day 1) until study end (Day 361)

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	27.1
--------------------	------

Reporting groups

Reporting group title	HBs-alum Group
-----------------------	----------------

Reporting group description:

Participants received 3 doses of GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide, at Day 1, Day 31 and Day 181.

Reporting group title	HBs-AS03 Group
-----------------------	----------------

Reporting group description:

Participants received 2 doses of GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03, adjuvant system, at Day 1 and Day 31.

Reporting group title	HBs-AS04 Group
-----------------------	----------------

Reporting group description:

Participants received 2 doses of GSK's Hepatitis B vaccine adjuvanted with GSK's AS04, adjuvant system, at Day 1 and Day 31.

Reporting group title	HBs-AS37_formulation 1 (Low dose) Group
-----------------------	---

Reporting group description:

Participants received 2 doses of GSK's HBsAg candidate vaccine adjuvanted with GSK's AS37 adjuvant system formulation 1 (Low dose), at Day 1 and Day 31.

Reporting group title	HBs-AS37_formulation 2 (High dose) Group
-----------------------	--

Reporting group description:

Participants received 2 doses of GSK's HBsAg candidate vaccine adjuvanted with GSK's AS37 adjuvant system formulation 2 (High dose), at Day 1 and Day 31.

Serious adverse events	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 25 (0.00%)	0 / 25 (0.00%)	0 / 24 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Infections and infestations			
Anal abscess			
subjects affected / exposed	0 / 25 (0.00%)	0 / 25 (0.00%)	0 / 24 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	HBs-AS37_formulation 1 (Low dose) Group	HBs-AS37_formulation 2 (High dose) Group	
------------------------	---	--	--

Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 25 (4.00%)	0 / 23 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Infections and infestations			
Anal abscess			
subjects affected / exposed	1 / 25 (4.00%)	0 / 23 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	HBs-alum Group	HBs-AS03 Group	HBs-AS04 Group
Total subjects affected by non-serious adverse events			
subjects affected / exposed	24 / 25 (96.00%)	21 / 25 (84.00%)	23 / 24 (95.83%)
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 25 (0.00%)	0 / 25 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Malaise			
subjects affected / exposed	10 / 25 (40.00%)	7 / 25 (28.00%)	8 / 24 (33.33%)
occurrences (all)	14	9	8
Administration site pain			
subjects affected / exposed	7 / 25 (28.00%)	20 / 25 (80.00%)	22 / 24 (91.67%)
occurrences (all)	7	32	37
Fatigue			
subjects affected / exposed	15 / 25 (60.00%)	14 / 25 (56.00%)	12 / 24 (50.00%)
occurrences (all)	18	18	18
Chills			
subjects affected / exposed	4 / 25 (16.00%)	4 / 25 (16.00%)	0 / 24 (0.00%)
occurrences (all)	4	4	0
Pyrexia			
subjects affected / exposed	2 / 25 (8.00%)	2 / 25 (8.00%)	1 / 24 (4.17%)
occurrences (all)	2	3	2
Injection site inflammation			

subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 25 (0.00%) 0	0 / 24 (0.00%) 0
Swelling face subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 25 (0.00%) 0	1 / 24 (4.17%) 1
Vaccination site discomfort subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	1 / 25 (4.00%) 1	0 / 24 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	1 / 25 (4.00%) 1	0 / 25 (0.00%) 0	0 / 24 (0.00%) 0
Throat irritation subjects affected / exposed occurrences (all)	1 / 25 (4.00%) 1	0 / 25 (0.00%) 0	0 / 24 (0.00%) 0
Nasal congestion subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 25 (0.00%) 0	1 / 24 (4.17%) 1
Psychiatric disorders Depression subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	1 / 25 (4.00%) 1	0 / 24 (0.00%) 0
Investigations Liver function test abnormal subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	1 / 25 (4.00%) 1	0 / 24 (0.00%) 0
C-reactive protein increased subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 25 (0.00%) 0	1 / 24 (4.17%) 1
Blood potassium increased subjects affected / exposed occurrences (all)	1 / 25 (4.00%) 1	0 / 25 (0.00%) 0	0 / 24 (0.00%) 0
Injury, poisoning and procedural complications Skin laceration subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	1 / 25 (4.00%) 1	0 / 24 (0.00%) 0

Arthropod sting subjects affected / exposed occurrences (all)	1 / 25 (4.00%) 1	0 / 25 (0.00%) 0	0 / 24 (0.00%) 0
Tendon injury subjects affected / exposed occurrences (all)	1 / 25 (4.00%) 1	0 / 25 (0.00%) 0	0 / 24 (0.00%) 0
Contusion subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 25 (0.00%) 0	1 / 24 (4.17%) 1
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 25 (0.00%) 0	0 / 24 (0.00%) 0
Nervous system disorders Headache subjects affected / exposed occurrences (all)	13 / 25 (52.00%) 17	12 / 25 (48.00%) 17	10 / 24 (41.67%) 15
Eye disorders Lacrimation increased subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 25 (0.00%) 0	0 / 24 (0.00%) 0
Gastrointestinal disorders Diarrhea subjects affected / exposed occurrences (all)	5 / 25 (20.00%) 6	4 / 25 (16.00%) 4	5 / 24 (20.83%) 5
Nausea subjects affected / exposed occurrences (all)	7 / 25 (28.00%) 8	1 / 25 (4.00%) 1	5 / 24 (20.83%) 6
Vomiting subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 25 (0.00%) 0	0 / 24 (0.00%) 0
Abdominal pain subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	1 / 25 (4.00%) 1	0 / 24 (0.00%) 0
Gingival pain subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 25 (0.00%) 0	1 / 24 (4.17%) 1

Renal and urinary disorders			
Dysuria			
subjects affected / exposed	0 / 25 (0.00%)	0 / 25 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 25 (0.00%)	1 / 25 (4.00%)	1 / 24 (4.17%)
occurrences (all)	0	1	1
Arthralgia			
subjects affected / exposed	3 / 25 (12.00%)	5 / 25 (20.00%)	3 / 24 (12.50%)
occurrences (all)	3	5	3
Myalgia			
subjects affected / exposed	10 / 25 (40.00%)	11 / 25 (44.00%)	15 / 24 (62.50%)
occurrences (all)	10	13	28
Neck pain			
subjects affected / exposed	0 / 25 (0.00%)	0 / 25 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 25 (0.00%)	0 / 25 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Musculoskeletal stiffness			
subjects affected / exposed	1 / 25 (4.00%)	0 / 25 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Infections and infestations			
Upper respiratory tract infection			
subjects affected / exposed	1 / 25 (4.00%)	0 / 25 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Tonsillitis			
subjects affected / exposed	1 / 25 (4.00%)	0 / 25 (0.00%)	1 / 24 (4.17%)
occurrences (all)	1	0	1
Nasopharyngitis			
subjects affected / exposed	1 / 25 (4.00%)	3 / 25 (12.00%)	1 / 24 (4.17%)
occurrences (all)	1	3	1
Bacterial vaginosis			
subjects affected / exposed	1 / 25 (4.00%)	0 / 25 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0

Cervicitis			
subjects affected / exposed	0 / 25 (0.00%)	0 / 25 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
COVID-19			
subjects affected / exposed	0 / 25 (0.00%)	0 / 25 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Chronic sinusitis			
subjects affected / exposed	0 / 25 (0.00%)	0 / 25 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	1 / 25 (4.00%)	0 / 25 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Lower respiratory tract infection			
subjects affected / exposed	0 / 25 (0.00%)	0 / 25 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis viral			
subjects affected / exposed	1 / 25 (4.00%)	0 / 25 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Fungal skin infection			
subjects affected / exposed	0 / 25 (0.00%)	0 / 25 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Fungal foot infection			
subjects affected / exposed	0 / 25 (0.00%)	0 / 25 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Rhinitis			
subjects affected / exposed	0 / 25 (0.00%)	0 / 25 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	1
Pharyngitis streptococcal			
subjects affected / exposed	1 / 25 (4.00%)	0 / 25 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0
Viral infection			
subjects affected / exposed	0 / 25 (0.00%)	0 / 25 (0.00%)	0 / 24 (0.00%)
occurrences (all)	0	0	0
Viral upper respiratory tract infection			
subjects affected / exposed	1 / 25 (4.00%)	0 / 25 (0.00%)	0 / 24 (0.00%)
occurrences (all)	1	0	0

Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	4 / 25 (16.00%)	5 / 25 (20.00%)	2 / 24 (8.33%)
occurrences (all)	4	6	2
Increased appetite			
subjects affected / exposed	0 / 25 (0.00%)	0 / 25 (0.00%)	1 / 24 (4.17%)
occurrences (all)	0	0	2

Non-serious adverse events	HBs- AS37_formulation 1 (Low dose) Group	HBs- AS37_formulation 2 (High dose) Group	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	23 / 25 (92.00%)	23 / 23 (100.00%)	
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 25 (4.00%)	0 / 23 (0.00%)	
occurrences (all)	1	0	
General disorders and administration site conditions			
Malaise			
subjects affected / exposed	4 / 25 (16.00%)	4 / 23 (17.39%)	
occurrences (all)	6	4	
Administration site pain			
subjects affected / exposed	18 / 25 (72.00%)	21 / 23 (91.30%)	
occurrences (all)	30	32	
Fatigue			
subjects affected / exposed	14 / 25 (56.00%)	11 / 23 (47.83%)	
occurrences (all)	19	16	
Chills			
subjects affected / exposed	1 / 25 (4.00%)	3 / 23 (13.04%)	
occurrences (all)	2	3	
Pyrexia			
subjects affected / exposed	2 / 25 (8.00%)	1 / 23 (4.35%)	
occurrences (all)	3	1	
Injection site inflammation			
subjects affected / exposed	1 / 25 (4.00%)	0 / 23 (0.00%)	
occurrences (all)	1	0	
Swelling face			

subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 23 (0.00%) 0	
Vaccination site discomfort subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 23 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	1 / 25 (4.00%) 1	0 / 23 (0.00%) 0	
Throat irritation subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 23 (0.00%) 0	
Nasal congestion subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 23 (0.00%) 0	
Psychiatric disorders Depression subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 23 (0.00%) 0	
Investigations Liver function test abnormal subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 23 (0.00%) 0	
C-reactive protein increased subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 23 (0.00%) 0	
Blood potassium increased subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 23 (0.00%) 0	
Injury, poisoning and procedural complications Skin laceration subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	2 / 23 (8.70%) 2	
Arthropod sting subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 23 (0.00%) 0	

Tendon injury subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 23 (0.00%) 0	
Contusion subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 23 (0.00%) 0	
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	1 / 23 (4.35%) 1	
Nervous system disorders Headache subjects affected / exposed occurrences (all)	13 / 25 (52.00%) 18	12 / 23 (52.17%) 17	
Eye disorders Lacrimation increased subjects affected / exposed occurrences (all)	1 / 25 (4.00%) 1	0 / 23 (0.00%) 0	
Gastrointestinal disorders Diarrhea subjects affected / exposed occurrences (all)	1 / 25 (4.00%) 1	3 / 23 (13.04%) 3	
Nausea subjects affected / exposed occurrences (all)	1 / 25 (4.00%) 2	2 / 23 (8.70%) 3	
Vomiting subjects affected / exposed occurrences (all)	1 / 25 (4.00%) 1	1 / 23 (4.35%) 1	
Abdominal pain subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 23 (0.00%) 0	
Gingival pain subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 23 (0.00%) 0	
Renal and urinary disorders Dysuria			

subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 23 (0.00%) 0	
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	1 / 25 (4.00%)	0 / 23 (0.00%)	
occurrences (all)	1	0	
Arthralgia			
subjects affected / exposed	3 / 25 (12.00%)	2 / 23 (8.70%)	
occurrences (all)	3	2	
Myalgia			
subjects affected / exposed	9 / 25 (36.00%)	13 / 23 (56.52%)	
occurrences (all)	13	16	
Neck pain			
subjects affected / exposed	1 / 25 (4.00%)	1 / 23 (4.35%)	
occurrences (all)	1	1	
Pain in extremity			
subjects affected / exposed	0 / 25 (0.00%)	0 / 23 (0.00%)	
occurrences (all)	0	0	
Musculoskeletal stiffness			
subjects affected / exposed	0 / 25 (0.00%)	0 / 23 (0.00%)	
occurrences (all)	0	0	
Infections and infestations			
Upper respiratory tract infection			
subjects affected / exposed	1 / 25 (4.00%)	0 / 23 (0.00%)	
occurrences (all)	1	0	
Tonsillitis			
subjects affected / exposed	0 / 25 (0.00%)	0 / 23 (0.00%)	
occurrences (all)	0	0	
Nasopharyngitis			
subjects affected / exposed	3 / 25 (12.00%)	2 / 23 (8.70%)	
occurrences (all)	3	2	
Bacterial vaginosis			
subjects affected / exposed	0 / 25 (0.00%)	0 / 23 (0.00%)	
occurrences (all)	0	0	
Cervicitis			

subjects affected / exposed	0 / 25 (0.00%)	0 / 23 (0.00%)	
occurrences (all)	0	0	
COVID-19			
subjects affected / exposed	0 / 25 (0.00%)	0 / 23 (0.00%)	
occurrences (all)	0	0	
Chronic sinusitis			
subjects affected / exposed	0 / 25 (0.00%)	1 / 23 (4.35%)	
occurrences (all)	0	1	
Oral herpes			
subjects affected / exposed	0 / 25 (0.00%)	0 / 23 (0.00%)	
occurrences (all)	0	0	
Lower respiratory tract infection			
subjects affected / exposed	0 / 25 (0.00%)	1 / 23 (4.35%)	
occurrences (all)	0	1	
Gastroenteritis viral			
subjects affected / exposed	0 / 25 (0.00%)	0 / 23 (0.00%)	
occurrences (all)	0	0	
Fungal skin infection			
subjects affected / exposed	0 / 25 (0.00%)	0 / 23 (0.00%)	
occurrences (all)	0	0	
Fungal foot infection			
subjects affected / exposed	0 / 25 (0.00%)	0 / 23 (0.00%)	
occurrences (all)	0	0	
Rhinitis			
subjects affected / exposed	0 / 25 (0.00%)	0 / 23 (0.00%)	
occurrences (all)	0	0	
Pharyngitis streptococcal			
subjects affected / exposed	0 / 25 (0.00%)	0 / 23 (0.00%)	
occurrences (all)	0	0	
Viral infection			
subjects affected / exposed	0 / 25 (0.00%)	1 / 23 (4.35%)	
occurrences (all)	0	1	
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 25 (0.00%)	0 / 23 (0.00%)	
occurrences (all)	0	0	
Metabolism and nutrition disorders			

Decreased appetite subjects affected / exposed occurrences (all)	1 / 25 (4.00%) 1	1 / 23 (4.35%) 1	
Increased appetite subjects affected / exposed occurrences (all)	0 / 25 (0.00%) 0	0 / 23 (0.00%) 0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
10 August 2022	The amendment was developed to update the study holding rules, delete reference to emergency unblinding, and to preform minor editorial corrections.
17 November 2023	The amendment was developed to revise the enrollment number necessary for the study.
17 September 2024	The amendment was developed to update the tertiary objectives based on data obtained in the main immunogenicity analysis and availability of alternative assays.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported